Power generating and control apparatus for the treatment of tissue

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is generally related to medical devices, systems, and methods which apply (or otherwise make use of) energy, as well as to other fields in which accurate control over electrical energy is beneficial. In exemplary embodiments, the invention provides an energy generating and control apparatus for the selective delivery of energy dosage during catheter-based treatment for luminal diseases, particularly for atherosclerotic plaque, vulnerable or “hot” plaque, and the like.

2. Discussion of Related Art

Physicians use catheters to gain access to, and repair, interior tissues of the body, particularly within the lumens of the body such as blood vessels. For example, balloon angioplasty and other catheters often are used to open arteries that have been narrowed due to atherosclerotic disease.

Balloon angioplasty is often effective at opening an occluded blood vessel, but the trauma associated with balloon dilation can impose significant injury, so that the benefits of balloon dilation may be limited in time. Stents are commonly used to extend the beneficial opening of the blood vessel.

Stenting, in conjunction with balloon dilation, is often the preferred treatment for atherosclerosis. In stenting, a collapsed metal framework is mounted on a balloon catheter that is introduced into the body. The stent is manipulated into the site of occlusion and expanded in place by the dilation of the underlying balloon. Stenting has gained widespread acceptance, and produces generally acceptable results in many cases. Along with treatment of blood vessels, particularly the coronary arteries, stents can also be used in treating many other tubular obstructions within the body, such as for treatment of reproductive, gastrointestinal, and pulmonary obstructions.

Restenosis or a subsequent narrowing of the body lumen after stenting has occurred in a significant number of cases. More recently, drug coated stents (such as Johnson and Johnson's Cypher™ stent, the associated drug comprising Sirolimus™) have demonstrated a markedly reduced restenosis rate, and others are developing and commercializing alternative drug eluting stents. In addition, work has also been initiated with systemic drug delivery (intravenous or oral) that may also improve the procedural angioplasty success rates.

While drug-eluting stents appear to offer significant promise for treatment of atherosclerosis in many patients, there remain many cases where stents either cannot be used or present significant disadvantages. Generally, stenting leaves an implant in the body. Such implants can present risks, including mechanical fatigue, corrosion, and the like, particularly when removal of the implant is difficult and involves invasive surgery. Stenting may have additional disadvantages for treating diffuse artery disease, for treating bifurcations, for treating areas of the body susceptible to crush, and for treating arteries subject to torsion, elongation, and shortening.

A variety of modified restenosis treatments or restenosis-inhibiting occlusion treatment modalities have also been proposed, including intravascular radiation, cryogenic treatments, ultrasound energy, and the like, often in combination with balloon angioplasty and/or stenting. While these and different approaches show varying degrees of promise for decreasing the subsequent degradation in blood flow following angioplasty and stenting, the trauma initially imposed on the tissues by angioplasty remains problematic.

More recently, still further disadvantages of dilation have come to light. These include the existence of vulnerable plaque, which can rupture and release materials that may cause myocardial infarction or heart attack.

A number of alternatives to stenting and balloon angioplasty so as to open stenosed arteries have also been proposed. For example, a wide variety of atherectomy devices and techniques have been disclosed and attempted. Despite the disadvantages and limitations of angioplasty and stenting, atherectomy has not gained the widespread use and success rates of dilation-based approaches.

Additionally, methods in the art of debulking diseased tissue to reduce or eliminate lesions, such as atherectomy and ablation, generally provide few if any means for protecting healthy tissue from being damaged through the course of treating diseased tissue.

In light of the above, it would be advantageous to provide new devices, systems, and methods for remodeling of the lumens of the body, and particularly tissue of the blood vessels. It would further be desirable to avoid significant cost or complexity while providing structures which could remodel body lumens without having to resort to the trauma of extreme dilation, damage to neighboring healthy tissue, and to allow the opening of blood vessels and other body lumens which are not suitable for stenting.

BRIEF SUMMARY OF THE INVENTION

The present invention relates to the treatment of tissue through the delivery of energy in a controlled dosage. Tissue may be targeted by applying energy, making tissue characterization analysis, and further selectively energizing a plurality of energy delivery surfaces through the use of an energy source with a controller.

In exemplary embodiments, the apparatus for power delivery may comprise a power generating circuit further comprising: a power generating source, an amplifier block, a power output set point controller, voltage and current feedback at the point of power delivery used to measure impedance at the power delivery target, a peak effective power sensor block receiving the voltage and current feedback, and a Proportional, Integral, Derivative (PID) controller receiving a signals from the power output set point controller and the peak effective power sensor block, whereby the PID controller modulates total input voltage to the power amplifier block such that the output of power from the circuit is maintained within a range about the power output set point in response to measured impedance at the power delivery target.

In some exemplary embodiments output power is Radio Frequency (RF) power while in alternate exemplary embodiments power may be in the form of ultrasound, microwave, laser, or other suitable forms of energy.

In some exemplary embodiments the apparatus for delivery may be further comprised of a catheter, wherein the catheter may be further comprised to have a plurality of energy delivery surfaces, most preferably a plurality of energy delivery surfaces mounted to an inflatable balloon.

In some exemplary embodiments there is provided a method for preferably calibrating the apparatus comprised of using a variety of loads to calculate power circuit impedance with vector network analysis such that the measure of real-time change in circuit load impedance during power generation may represent the real-time change in impedance at the power delivery target of the apparatus.

In some exemplary embodiments there is provided a method comprising identifying an accessory attached to the apparatus by repeating calibration to ascertain the type of attached accessory based on its impedance characteristics.

In some exemplary embodiments there is provided a method of applying energy in a controlled manner to achieve a substantially uniform bulk temperature distribution in target tissue.

In some exemplary embodiments there is provided a method for applying energy to nerve tissue to alter the activity of the nerve for the purpose of achieving a beneficial biological response.

Preferred embodiments of the present invention may be used in procedures for achieving therapeutic biologic effects in tissue. Most preferably, the present invention may be used at any point and time before, during, and/or after an angioplasty procedure.

In another aspect, the invention provides a power generating apparatus for treatment of a target tissue. The power generating apparatus comprises a frequency synthesizer generating a frequency signal. A power amplifier operatively couples the frequency synthesizer to a power output. The output is coupleable to the target tissue, and a power sensor is configured to receive voltage and current feedback from the target tissue, and to output measured impedance at the target tissue. A controller couples the power sensor to the power amplifier. The controller has an input for receiving a power set point and transmits, in response to the power set point and the measured impedance at the target tissue, a modulating signal to the power amplifier such that power output from the power amplifier to the target tissue per the frequency signal is maintained within a desired range about the power set point.

Optionally, the frequency synthesizer comprises a digital frequency synthesizer such as a Direct Digital Synthesizer (DDS), and a digital-to-analog converter couples the frequency synthesizer to the power amplifier. The energy output from the apparatus to the target tissue typically comprises RF energy, but may alternatively comprise microwave energy or the like. In many embodiments, the power generating apparatus is included in a system, with the system also including an elongate catheter. The catheter may have an elongate flexible catheter body with a distal end configured for advancing into a blood vessel. A connector can be coupled to a proximal end of the body, with the connector being configured to couple to the output so that, in use, the catheter couples the output to the target tissue adjacent the distal end. The impedance of the target tissue as measured by the power generating apparatus of the system is often independent of an impedance of the power generating apparatus, the catheter body, and/or the like.

In another aspect, the invention provides a calibration module for calibrating an RF system in preparation for treatment of a target tissue. The RF system comprises a power generating apparatus including an impedance measurement circuit. The module comprises a first input for receiving a first impedance from the impedance measurement circuit of the power generating apparatus. The first impedance corresponding to a low circuit load on the power generating apparatus prior to coupling of the power generating apparatus to the target tissue. A second input similarly receives a second impedance from the impedance measurement circuit but corresponding to a high circuit load on the power generating apparatus (again prior to coupling of the power generating apparatus to the target tissue). A third input receives a similar third impedance from the impedance measurement circuit between the high load and the low load. A processor is configured to calculate system impedance using the measured impedances so as to facilitate, in response to a measure of real-time changes in overall circuit load impedance during power application to the target tissue, changes in impedance at the target tissue. The overall circuit load impedance comprising impedance of the power generating apparatus and the impedance at target tissue.

Typically, the RF system further comprises a catheter or other coupling device for coupling the power generating apparatus to the target tissue. More generally, the overall circuit of the systems described herein may, during use, include a power generating circuit, a power output target circuit, and a coupling circuit, with each of these portions of the overall system circuit contributing respective impedance portions to the overall impedance of the system. To help more accurately characterize the impedance contributions of these portions of the overall circuit, and to more accurately measure impedance at the target tissue (or other power output target), the processor can be configured to calculate another system impedance of the power generating apparatus and the catheter after coupling of the catheter to the power generating apparatus and before coupling of the catheter to the target tissue.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 schematically illustrates one embodiment of a power generation and control apparatus for use with a balloon catheter having electrodes in a power system.

FIG. 2 schematically illustrates one embodiment of an inflatable balloon for use in the apparatus of FIG. 1.

FIG. 3A schematically illustrates a cross-sectional view of the balloon of FIG. 2.

FIG. 3B schematically illustrates one embodiment of electrodes for use in tissue analysis and selective energy treatment using the apparatus of FIG. 1.

FIG. 4 schematically illustrates one embodiment of a power generation and control circuit.

FIG. 5 schematically illustrates one embodiment of a DDS down conversion section of a peak effective power sensor block shown in FIG. 4.

FIG. 6 schematically illustrates one embodiment of the DC baseband processing section of a peak effective power sensor block shown in FIG. 4.

FIG. 7 schematically illustrates one embodiment of a PID control block shown in FIG. 4.

FIG. 8 schematically illustrates a two-port network design for sensing and controlling incident and reflected power.

FIG. 9A schematically illustrates one embodiment of the amplifier block shown in FIG. 4.

FIG. 9B illustrates the “soft current limit” relationship for the amplifier block shown in FIG. 4.

FIG. 10 is an exemplary plot of maximum and minimum measured current in a tissue treatment embodiment of the apparatus shown in FIG. 1.

FIG. 11 is an exemplary plot of maximum and minimum measured impedance in a issue treatment embodiment of the apparatus shown in FIG. 1.

FIG. 12 is an exemplary plot of maximum and minimum measured voltage in a tissue treatment embodiment of the apparatus shown in FIG. 1.

FIG. 13 is an exemplary plot of measured power at the target site and at the power generator in a tissue treatment embodiment of the apparatus shown in FIG. 1.

FIGS. 14A & B schematically illustrate a substantially uniform bulk temperature distribution in luminal tissue using empirically derived energy dosage and impedance control for an embodiment of the apparatus shown in FIG. 1.

FIGS. 15A & B schematically illustrate a substantially uniform bulk temperature distribution in luminal tissue using energy dosage derived using accumulated damage theory for an embodiment of the apparatus shown in FIG. 1.

FIG. 16 schematically illustrates a method and system for calibrating a power generating system so as facilitate accurate measurement of impedance at a target power output.

DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the present invention relate to a power generating and control apparatus, often for the treatment of targeted tissue in order to achieve a therapeutic effect. Preferably, the target tissue is luminal tissue, which may further comprise diseased tissue such as that found in arterial disease.

While the disclosure focuses on the use of the technology in the vasculature, the technology would also be useful for other luminal obstructions. Other anatomical structures in which the present invention may be used are the esophagus, the oral cavity, the nasopharyngeal cavity, the auditory tube and tympanic cavity, the sinus of the brain, the arterial system, the venous system, the heart, the larynx, the trachea, the bronchus, the stomach, the duodenum, the ileum, the colon, the rectum, the bladder, the ureter, the ejaculatory duct, the vas deferens, the urethra, the uterine cavity, the vaginal canal, and the cervical canal.

Devices for heating tissue using RF, ultrasound, microwave and laser energies have been disclosed in U.S. patent application Ser. No. 11/975,474, filed on Oct. 18, 2007, entitled “Inducing Desirable Temperature Effects on Body Tissue”, U.S. patent application Ser. No. 11/975,383, filed on Oct. 18, 2007, entitled “System for Inducing Desirable Temperature Effects On Body Tissue”, U.S. patent application Ser. No. 11/122,263, filed on May 3, 2005, entitled “Imaging and Eccentric Atherosclerotic Material Laser Remodeling and/or Ablation Catheter” and U.S. application Ser. No. 12/564,268, filed on Sep. 22, 2009, entitled “Inducing Desirable Temperature Effects on Body Tissue Using Alternate Energy Sources”, the full disclosures of which are incorporated herein by reference, may be combined with the present invention.

Power Generation and Control

In many embodiments of the present invention, the power generating and control apparatus may include internal circuitry 400, control software, a user interface 102, and power generation and control enclosure 101 housing the circuitry 400 and user interface 102.

Referring to FIGS. 1 and 4, the internal circuitry 400, housed within the enclosure 101, may include a direct digital synthesizer (DDS) block 401 whose digital code output may be preferably passed through digital-to-analog converter (DAC) 402. DAC 402 converts the digital code signal from DDS block 401 to an analog voltage signal 414. Voltage signal 414 and an analog modulating voltage signal 413 preferably pass through amplifier block 403, resulting in target power output 404. Measurements of voltage and current load at the target power output 404 may be measured by voltage sensor 405 and current sensor 407, preferably the signals from which may be passed through analog-to-digital converters (ADC) 406 and 408 respectively. The digital voltage signal from ADC 406 and the digital current signal from ADC 408 are preferably received by peak effective power sensor 410, where the effective power output of the power generation and control apparatus at the power delivery target 404 may be measured in real-time. Power set point control 409 is based on software-programmed operating parameters.

In a preferred embodiment shown in FIGS. 5 and 6, the peak effective power sensor block 410 may comprise a DDS 500 used to mix voltage sense signal V (from 406) and current sense signal I (from 408) down to DC baseband signals, preferably generating a voltage output with low-pass filter 502 after passing sense signal V through rounding gate 501, and a current output with low-pass filter 504 after passing sense signal I through rounding gate 503. The voltage and current output from target power output 404 include in-phase current 507, in-phase voltage 505, and quadrature current 508, quadrature voltage 506 components. It is preferable for signals within the circuit 410 to comprise in-phase and quadrature components because blocks within the circuit 410 may then recognize the instantaneous amplitude, frequency, and phase shift between the components of a signal and between the several signals passing through the blocks of circuit 410. The digital output signals from low-pass filter 502 and low-pass filter 504 of peak effective power sensor 410 may then be transmitted to the power calculation circuits shown in FIG. 6.

Now referring to FIG. 6, voltage amplitude may be calculated by summing the squares of the in-phase voltage signal 505 and the quadrature voltage signal 506, and passing the sum through square root circuit 602. Current amplitude may be calculated by summing the squares of the in-phase current signal 507 and the quadrature current signal 508, and passing the sum through square root circuit 606. Uncorrected power may preferably be calculated by multiplying voltage amplitude and current amplitude.

The phase of the voltage signal may preferably be calculated by passing the quadrature component 506 of the voltage signal and the in-phase component 505 of the voltage signal through inverse tangent gate 603. Similarly, the phase of the current signal may preferably be calculated by passing the quadrature component 508 of the current signal and the in-phase component 507 of the current signal through inverse tangent gate 607. Cosine gate 608 preferably receives the difference output from inverse tangent gates 603 and 607 such that a power factor correction may be calculated. The peak effective power may be calculated by multiplying the uncorrected power by the output of the cosine gate 608 and rounding the result with rounding gate 609.

Although FIGS. 5 and 6 represent a most preferred embodiment, peak effective power may be calculated using other means, such as multiplying the instantaneous RF voltage and RF current waveforms together and integrating the resulting signal to obtain an average value; the means for calculating peak effective power being selected from any available means suitable for the type of power used and suitable for the components comprising the circuitry of the apparatus disclosed and described herein.

Now referring to FIGS. 9A and 9B, amplifier block 403 may include variable gain amplifier 901, receiving voltage input 414 from DDS block 400 and modulating voltage signal 413 from PID controller 411, and power amplifier 902. Power amplifier 902 has a “soft current limit” as shown in FIG. 9B, whereby the available output voltage decreases in a tailored manner as the required output current is increased. The advantage of power amplifier 902 having a soft current limit is that the maximum output power delivered can be inherently limited by the characteristic of the current limit circuit, wherein the current limit circuit may provide a substantially constant maximum available output power across a broad range of load impedances, most preferably exceeding about a decade of load impedance. An additional advantage of the soft current limit scheme is that, when implemented using switched mode power supply technology, extremely high power amplifier efficiencies can be achieved across a broad range of load impedances, preferably exceeding about a decade of load impedance.

Control of target power output 404 may be preferably achieved through power set point control 409, and peak effective power sensor block 410 passing signals to PID controller 411 that may ultimately produce modulating voltage signal 413 passing into amplifier block 403. Power output set point control 409 may provide a software control signal based on programmed operating parameters, which in many embodiments may be set to promote remodeling of diseased tissue in a manner that avoids damage to surrounding healthy tissue. By taking real-time load measurements in-phase and in quadrature at power output 404, circuit 400 is thereby able to characterize and respond to load variations by modulating output such that output may vary within a relatively small range from set point. Power output variation about the set point may be about ±2%, however, preferred embodiments may regulate output variation in other ranges, such as, about ±5%, about ±10%, about ±15%, and about ±20% or greater.

Now referring to FIGS. 4 and 7, PID controller 411 preferably receives output signals from power output set point 409 and peak effective power output block 410. PID controller 411 may comprise hardware and or software modules which perform proportional 701 (“P”), integral 702 (“I”), and derivative 703 (“D”) calculations K_pe(t), K_{i 0}∫^τe(τ)dτ, and K_dde(τ)/dt, respectively, which may be expressed in the ideal form of the equation V_m(t)=K_pe(t)+K_{i 0}∫^τe(τ)dτ+K_dde(τ)/dt, where, V_m(t) represents the computed modulating voltage 413 as a function of time in response to measured power at the output 404, the peak effective power calculation 410, and power set point 409.

Wherein:

K_pe(t) represents the proportional reaction to error in the measured/calculated power to the desired power;

K_{i 0}∫^τe(τ)dτ represents the integral reaction to the sum of the errors in the measured/calculated power to the desired power, where τ represents the period of time integrated over and e(t) represents the calculated power at the present time t; and,

K_dde(τ)/dt represents the derivative reaction to the rate of change in the error of the measured/calculated power to the desired power.

In the most preferred embodiment, the PID equation may be expressed in the more common “standard” or “industrial” form V_m(t)=K_p[e(t)+1/T_{i 0}∫^τe(τ)dτ+T_dde(τ)/dt], where, constants K_iand K_dare replaced with T_iand T_d, representing the integral and derivative time values respectively. The standard form provides the advantage of simplifying the derivation and use of constants in the control equation.

In a preferred embodiment, time interval “t” of about 160 microseconds exists between power measurements and calculations of power at the target power output 404. The output calculation of the PID control loop of 411 may be referred to as the “manipulated variable” or modulating voltage 414 that is preferably used to drive amplifier block 403 to regulate output power closely about a set point. The constants K_i, K_p, and K_dhelp to define how quickly circuit 400 may respond to increasing errors in output 404, or how quickly to modulate amplifier block 403 to reduce error in output at 404 as compared to set point 409. The power calculation 704 is preferably based on the quadrature 506 and in-phase 505 voltage components, and the quadrature 507 and in-phase 508 current components of the output of DDS block 401.

Now referring to FIGS. 1 and 8, the overall apparatus 100, which includes both the power generator and control apparatus of enclosure 101 and an attached accessory 100′ (which, for example, may comprise the catheter assembly 108 and connector 103 of FIG. 1), may utilize a communication schema such as that shown in FIG. 8. Although FIG. 8 depicts a preferred embodiment utilizing a two-port network 800, other numbers of communication ports may be employed depending on the desired arrangement for a given power control application. In general there are usually significant RF losses, reflections and phase shifts between voltage sensor 405, current sensor 407 and the target load (tissue) 404. These RF losses, reflections and phase shifts cause significant deviations in the actual power delivered to the load (tissue) 404 and additionally cause significant errors in the measurement of load (tissue) impedance. In a preferred embodiment, generalized 2-port reflectometry is used to compensate for all the RF losses, reflections and phase shifts in the RF path, both with respect to accurately controlling load (tissue) power and accurately measuring load (tissue) impedance. For this purpose, the two-port network 800 may comprise a series of control computations utilizing incident and reflected power waves between power generator and control apparatus of enclosure 101, attached accessory 100′, and the load at the target power output 404, preferably resulting in controlled voltage and current output 800V&I by power generator and control apparatus of enclosure 101.

Incident power waves are denoted by subscript “a_n”, reflected power waves are denoted by subscript “b_n”, incident and reflected power at 404 are denoted by “a_L” and “b_L” respectively. For the purpose of clarity in the following description of the mathematic operations represented in FIG. 8, mathematic equations shall omit the descriptive element number “800” shown in FIG. 8 to simplify the meaning of the equations described.

The two-port network definition of scattering parameters in terms of incident and reflected power waves (a_nand b_n, respectively) are defined as:

$\begin{matrix} a_{1} = \frac{1}{2} (\frac{V_{1}}{\sqrt{Z_{o}}} + I_{1} \sqrt{Z_{o}}) . & 1 \\ b_{1} = \frac{1}{2} (\frac{V_{1}}{\sqrt{Z_{o}}} - I_{1} \sqrt{Z_{o}}) . & 2 \\ a_{2} = \frac{1}{2} (\frac{V_{2}}{\sqrt{Z_{o}}} + I_{2} \sqrt{Z_{o}}) . & 3 \\ b_{2} = \frac{1}{2} (\frac{V_{2}}{\sqrt{Z_{o}}} - I_{2} \sqrt{Z_{o}}) . & 4 \end{matrix}$

Wherein, a1 and b1 are the incident and reflected power waves at generator 101, and a₂and b₂are the incident and reflected power waves at the load (electrodes 112, for example).

The S-Parameter matrix for the two-port network along with expanded equations may be defined as:

$\begin{matrix} (\begin{matrix} b_{1} \\ b_{2} \end{matrix}) = (\begin{matrix} S_{11} & S_{12} \\ S_{21} & S_{22} \end{matrix}) (\begin{matrix} a_{1} \\ a_{2} \end{matrix}) . & 5 \\ b_{1} = S_{11} a_{1} + S_{12} a_{2} . & 6 \\ b_{2} = S_{12} a_{1} + S_{22} a_{2} . & 7 \end{matrix}$

The complex impedances at the generator 101, which may comprise circuit 400, and at the load 404 may be respectively defined as rho (ρ) and gamma (Γ). Rho and gamma preferably may then be defined using the incident and reflected power waves as:

$\begin{matrix} ρ = \frac{b_{1}}{a_{1}} . & 8 \\ Γ = \frac{a_{2}}{b_{2}} . & 9 \end{matrix}$

The reverse transform from rho space to gamma space may now be derived using the relationships in Equations 1 through 9, as shown below:

$\begin{matrix} \frac{1}{Γ} = \frac{b_{2}}{a_{2}} = S_{22} + \frac{S_{12} a_{1}}{a_{2}} . & 10 \\ \frac{1}{Γ} - S_{22} = \frac{S_{12} a_{1}}{a_{2}} . & 11 \\ \frac{1}{\frac{1}{Γ} - S_{22}} = \frac{a_{2}}{S_{12} a_{1}} . & 12 \\ \frac{a_{2}}{a_{1}} = S_{12} (\frac{1}{\frac{1}{Γ} - S_{22}}) . & 13 \\ ρ = \frac{b_{1}}{a_{1}} = S_{11} + \frac{S_{12} a_{2}}{a_{1}} . & 14 \\ ρ = S_{11} + S_{12}^{2} (\frac{Γ}{1 - S_{22} Γ}) . & 15 \\ ρ = S_{11} + S_{12}^{2} (\frac{Γ}{1 - S_{22} Γ}) . & 16 \\ ρ = \frac{S_{11} (1 - S_{22} Γ) + S_{12}^{2} Γ}{1 - S_{22} Γ} . & 17 \\ ρ = \frac{S_{11} + (S_{12}^{2} - S_{11} S_{22}) Γ}{1 - S_{22} Γ} . & 18 \end{matrix}$

Equation 18 provides the explicit form of the reverse transform from rho space to gamma space. The scattering parameters may be grouped and preferably defined as reverse transform coefficients A, B, and D in the following form:

A=S₁₁ 19.
B=S₁₂²−S₁₁S₂₂ 20.
D=−S₂₂ 21.

Equation 18 may be simplified by substituting coefficients A, B, and D into the preferred explicit form of the reverse transform, thereby providing a preferred general form of the reverse transform:

$\begin{matrix} ρ = \frac{A + B Γ}{1 + D Γ} . & 22 \end{matrix}$

Using Equation 22, and solving for gamma, the forward transform may be derived in preferred form:

$\begin{matrix} ρ + D Γρ = A + B Γ . & 23 \\ D Γρ - B Γ = A - ρ . & 24 \\ Γ (D ρ - B) = A - ρ . & 25 \\ Γ = \frac{A - ρ}{D ρ - B} . & 26 \\ Γ = \frac{(- \frac{A}{B}) + \frac{1}{B} ρ}{1 + (- \frac{D}{B}) ρ} . & 27 \end{matrix}$

In a similar fashion as Equations 19 through 21, forward transform coefficients A′, B′, and D′ may preferably serve to simplify the equation between gamma and rho space as shown:

$\begin{matrix} A^{'} = (- \frac{A}{B}) . & 28 \\ B^{'} = (\frac{1}{B}) . & 29 \\ D^{'} = (- \frac{D}{B}) . & 30 \end{matrix}$

Equation 12 may be simplified by substituting coefficients A′, B′, and D′ into the preferred explicit form of the forward transform, thereby providing a preferred general form of the forward transform:

$\begin{matrix} Γ = \frac{A^{'} + B^{'} ρ}{1 + D^{'} ρ} . & 31 \end{matrix}$

Forward power at the load 404 may be preferably defined as the magnitude of the square of the power wave incident on load 404:

P_FL=|a_L|²=|b₂|² 32.

Similarly, the reverse power from load 404 may be defined as the magnitude of the square of the power wave reflected by load 404:

P_RL=|b_L|²=|a₂|² 33.

Through the relationships defined above, the power absorbed at the target power output load 404, may be defined as incident power minus reflected power through the relationships:

$\begin{matrix} P_{L} = P_{AL} - P_{RL} . & 34 \\ P_{L} = {\langle a_{L} \rangle}^{2} - {\langle b_{L} \rangle}^{2} . & 35 \\ P_{L} = {\langle a_{L} \rangle}^{2} {1 - \frac{{\langle b_{L} \rangle}^{2}}{{\langle a_{L} \rangle}^{2}}} . & 36 \end{matrix}$

and, substituting Equations 7, 9, and 32 into Equations 34 through 36, provides the expanded form of the relationships:

P_L=|a_L|²{1−|Γ|²} 37.
P_L=P_FL{1−|Γ|²} 38.
P_L=|b₂|²(1−|Γ|²) 39.
P_L=|S₁₂a₁+S₂₂a₂|²(1−|Γ|²) 40.

In the most preferred two-port network, incident and reflected power at port 1 may now be defined. Incident power at 800_a1may preferably be defined as the magnitude of the square of the power wave incident at 800_a1:

P_F1=|a₁|² 41.

and, reflected power at 800_b1may preferably be defined as the magnitude of the square of the power wave reflected at 800_b1:

P_R1=|b₁|² 42.

Power absorbed at port 1 (“P₁”) may be defined, using Equations 41 and 42, as the incident power at port 1 minus the reflected power at port 1:

P₁=|a₁|²−|b₁|²=|a₁|²(1−|ρ|²) 43.

which, may also be defined as the magnitude of the absorbed voltage multiplied by the magnitude of the absorbed current multiplied by the cosine of the angle between the absorbed voltage and absorbed current:

$\begin{matrix} P_{1} = \langle V \rangle \langle I \rangle \langle \cos ϕ \rangle = {\langle a_{1} \rangle}^{2} (1 - {\langle ρ \rangle}^{2}) . & 44 \\ {\langle a_{1} \rangle}^{2} = \frac{\langle V \rangle \langle I \rangle \langle \cos ϕ \rangle}{(1 - {\langle ρ \rangle}^{2})} . & 45 \end{matrix}$

Substituting Equation 9 into Equation 7 and solving for b₂may define the following relationships defined for 800_b2in FIG. 8:

$\begin{matrix} b_{2} - S_{22} a_{2} = S_{12} a_{1} . & 46 \\ b_{2} (1 - S_{22} \frac{a_{2}}{b_{2}}) = S_{12} a_{1} . & 47 \\ b_{2} (1 - S_{22} Γ) = S_{12} a_{1} . & 48 \\ b_{2} = \frac{S_{12} a_{1}}{(1 - S_{22} Γ)} . & 49 \end{matrix}$

The power at load 404 in FIG. 8 may now be defined by substituting Equation 49 into Equation 39 and expanding the numerator by substituting Equation 45 into Equation 51:

$\begin{matrix} P_{L} = {\langle \frac{S_{12} a_{1}}{(1 - S_{22} Γ)} \rangle}^{2} (1 - {\langle Γ \rangle}^{2}) . & 50 \\ P_{L} = \frac{{\langle S_{12} \rangle}^{2} {\langle a_{1} \rangle}^{2}}{{\langle (1 - S_{22} Γ) \rangle}^{2}} (1 - {\langle Γ \rangle}^{2}) . & 51 \\ P_{L} = \frac{{\langle S_{12} \rangle}^{2} \langle V \rangle \langle I \rangle \langle \cos ϕ \rangle (1 - {\langle Γ \rangle}^{2})}{(1 - {\langle ρ \rangle}^{2}) {\langle (1 - S_{22} Γ) \rangle}^{2}} . & 52 \end{matrix}$

In a preferred embodiment of the present invention, measurement of known impedances in circuit 400 of FIG. 4 may be made in order to define the transform coefficients A, B, D and A′, B′, D′, as can be understood with reference to FIG. 16. Most preferably, three measurements are taken at known circuit loads 404, most preferably, impedance Z_ρOis taken at load of about 1000Ω, impedance Z_ρSis taken at a load of about 50Ω, and impedance Z_ρLis taken at a load of about 150Ω, where the complex voltage and current measurements (800_V&Iof FIG. 8) at power generator and control apparatus 101 are used to calculate impedances Z_ρO, Z_ρS, and Z_ρLusing Equation 53 where SYSTEM_IMPEDANANCEis assigned the value 150Ω. However, known circuit loads and assigned SYSTEM_IMPEDANCEto compute Z_ρO, Z_ρS, and Z_ρLmay be performed at other values ranging between about zero Ohms and about infinite Ohms. As shown in FIG. 16, such a calibration method may begin 1601 prior to coupling of the power generation components to the target tissue, and ideally before coupling of attachment 100′ to the power generation circuit 400 of enclosure 101. Three differing loads are applied with impedances being taken 1602, 1603, and 1604 at each load. These measurements are taken with the components of circuit 400, and are input into a hardware and/or software module for the system characterization calculations described herein.

$\begin{matrix} Z_{ρ N} = \frac{(\frac{V_{N}}{I_{N}} - {SYSTEM}_{IMPEDANCE})}{(\frac{V_{N}}{I_{N}} + {SYSTEM}_{IMPEDANCE})} . & 53 \end{matrix}$

Solving Equation 53 may preferably involve a preliminary set of impedance measurements most preferably using network analysis, most preferably vector network analysis, to preferably provide impedances Z_ΓO, Z_ΓS, and Z_ΓLat the respective loads of about 1000Ω, about 50Ω, and about 150Ω. The six preferred impedance measurements Z_ΓO, Z_ΓS, Z_ΓLZ_ρO, Z_ρS, and Z_ρLmay then preferably be used to calculate the transform coefficients A′, B′, D′:

$\begin{matrix} D^{'} = \frac{(Z_{Γ S} - Z_{Γ O}) * (Z_{ρ O} - Z_{ρ L}) - (Z_{Γ O} - Z_{Γ L}) * (Z_{ρ S} - Z_{ρ O})}{\begin{matrix} (Z_{Γ O} * Z_{ρ O} - Z_{Γ S} * Z_{ρ S}) * (Z_{ρ O} - Z_{ρ L}) - \\ (Z_{Γ L} * Z_{ρ L} - Z_{Γ O} * Z_{ρ O}) * (Z_{ρ S} - Z_{ρ O}) \end{matrix}} . & 54 \\ B^{'} = \frac{Z_{Γ O} - Z_{Γ L} - D * (Z_{Γ L} * Z_{ρ L} - Z_{Γ O} * Z_{ρ O})}{(Z_{ρ O} - Z_{ρ L})} . & 55 \\ A^{'} = Z_{Γ S} - B * Z_{ρ S} + D * (Z_{Γ S} * Z_{ρ S}) . & 56 \end{matrix}$

The value of the coefficients preferably defined by Equations 54 through 56 may now be preferably used to calculate actual load impedances at target power output 404 of FIG. 4 using Equation 31, and the actual power applied at target power output 404 using Equation 52, thereby preferably providing a calculated modulating output voltage 413 from PID controller 411 such that output at 404 is accurately regulated about a set point based on real-time changes in load, and power delivery is maintained within a range as described herein.

In preferred embodiments actual power output at the power delivery point is most preferably based on measured complex impedance angle of applied load at output 404. Wherein, the load most preferably denotes tissue and the complex impedance angle preferably denotes the health or disease of tissue and/or the change in tissue state through the course of the use of apparatus 100. Furthermore, because impedance is a function of capacitance and resistance, real-time tissue capacitance and real-time tissue resistance may also be known based on measured data through the relationship between impedance, capacitance, and resistance:

$\begin{matrix} Z = ({SYSTEM}_{IMPEDANCE}) * \frac{(1 + Γ)}{(1 - Γ)} . & 57 \end{matrix}$

Recalling that impedance may have real and imaginary components, the relationship in Equation 57 may be further expressed and developed as follows:

$\begin{matrix} Z = \frac{1}{(\frac{1}{R} + jω C)} . & 58 \\ Z = \frac{1}{(\frac{1}{R} + jω C)} * \frac{(1 - jω CR)}{(1 - jω CR)} . & 59 \\ Z = \frac{R - jω {CR}^{2}}{(1 + ω^{2} C^{2} R^{2})} . & 60 \\ Z_{real} = \frac{R}{(1 + ω^{2} C^{2} R^{2})} . & 61 \\ Z_{imaginary} = \frac{- jω {CR}^{2}}{(1 + ω^{2} C^{2} R^{2})} . & 62 \end{matrix}$

where ω denotes the natural frequency of the circuit, C denotes real-time tissue capacitance as measured at the load, and R denotes real-time tissue resistance as measured at the load.

Solving Equation 61 for C²and substituting Equation 63 into Equation 62, and solving Equation 64 for C:

$\begin{matrix} C^{2} = \frac{R - Z_{Real}}{(ω^{2} R^{2} Z_{Real})} . & 63 \\ Z_{Imaginary} = \frac{- jω {CR}^{2}}{(1 + ω^{2} R^{2} * \frac{(R - Z_{Real})}{(ω^{2} R^{2} Z_{Real})})} . & 64 \\ C = \frac{- Z_{Imaginary}}{Z_{Real} ω R} . & 65 \end{matrix}$

By solving Equation 65 for ω²C²R²and substituting into Equation 61, the simplified relationship may be obtained:

$\begin{matrix} Z_{real} = \frac{R}{(1 + \frac{Z_{Imaginary}}{Z_{Real}})} . & 66 \end{matrix}$

Now, the real-time tissue resistance may be determined through the known value of impedance Z from Equation 57 by simplifying Equation 66 and solving for R:

$\begin{matrix} R = Z_{Real} * (1 + {(\frac{Z_{Imaginary}}{Z_{Real}})}^{2}) . & 67 \end{matrix}$

and real-time tissue capacitance may be determined by substituting Equation 67 into Equation 65 and solving for C:

$\begin{matrix} C = \frac{- Z_{Imaginary}}{Z_{Real}^{2} ω (1 + {(\frac{Z_{Imaginary}}{Z_{Real}})}^{2})} . & 68 \end{matrix}$

In the most preferred embodiments of the system or overall apparatus 100 of FIG. 1 may include circuit 400 of FIG. 4 and coupling apparatus or accessory 100′, which may together be employed in the characterization and selective treatment of tissue to promote a therapeutic response. The characterization and selective treatment of tissue based on impedance, imaging modalities, and energy modalities are described by U.S. Pat. No. 7,291,146 to Steinke, et al., issued on Nov. 6, 2007, entitled “Selectable Eccentric Remodeling and/or Ablation of Atherosclerotic Material”, and the above referenced U.S. application Ser. Nos. 11/392,231, 11/975,651, 11/617,519, 11/975,474, 11/975,383, 12/564,268, the full disclosures of which are incorporated herein by reference. In the most preferred embodiments, power output is RF energy, however, ultrasound, laser, microwave, and the like as disclosed and described in the preceding references, are also within the scope of the present invention.

Now referring to FIG. 4, in some embodiments DDS block 401, power output set point control 409, and peak effective power sensor block 410 comprise a field programmable gate array without an embedded processor. In other embodiments where a field programmable gate array comprises an internal processor, DDS block 401, power output set point control 409, peak effective power sensor block 410, and PID controller may be comprised within the field programmable gate array.

In some embodiments, generator and control apparatus 101 may include a processor or be coupled to a processor to control or record treatment. The processor will typically comprise computer hardware and/or software, often including one or more programmable processor units running machine readable program instructions or code for implementing some, or all of, one or more of the embodiments and methods described herein. The code will often be embodied in a tangible media such as a memory (optionally a read only memory, a random access memory, a non-volatile memory, or the like) and/or a recording media (such as a floppy disk, a hard drive, a CD, a DVD, a non-volatile solid-state memory card, or the like). The code and/or associated data and signals may also be transmitted to or from the processor via a network connection (such as a wireless network, an ethernet, an internet, an intranet, or the like), and some or all of the code may also be transmitted between components of a catheter system and within the processor via one or more bus, and appropriate standard or proprietary communications cards, connectors, cables, and the like will often be included in the processor. The processor may often be configured to perform the calculations and signal transmission steps described herein at least in part by programming the processor with the software code, which may be written as a single program, a series of separate subroutines or related programs, or the like. The processor may comprise standard or proprietary digital and/or analog signal processing hardware, software, and/or firmware, and may preferably have sufficient processing power to perform the calculations described herein during treatment of the patient, the processor optionally comprising a personal computer, a notebook computer, a tablet computer, a proprietary processing unit, or a combination thereof. Standard or proprietary input devices (such as a mouse, keyboard, touchscreen, joystick, etc.) and output devices (such as a printer, speakers, display, etc.) associated with modern computer systems may also be included, and processors having a plurality of processing units (or even separate computers) may be employed in a wide range of centralized or distributed data processing architectures.

In the most preferred embodiments control software for apparatus 100 may use a client-server schema to further enhance system ease of use, flexibility, and reliability. “Clients” are the system control logic; “servers” are the control hardware. A communications manager delivers changes in system conditions to subscribing clients and servers. Clients “know” what the present system condition is, and what command or decision to perform based on a specific change in condition. Servers perform the system function based on client commands. Because the communications manager is a centralized information manager, new system hardware preferably may not require changes to prior existing client-server relationships; new system hardware and its related control logic may then merely become an additional “subscriber” to information managed through the communications manager. This control schema preferably provides the benefit of having a robust central operating program with base routines that are fixed; preferably no change to base routines may be necessary in order to operate new circuit components designed to operate with the system.

Accessories for Tissue Treatment

In some embodiments, the overall system or apparatus 100 of FIG. 1 may, along with the power generation apparatus, further include attached accessories, which most preferably may include an intraluminal catheter 108 having an energy delivery surface comprised therein.

In many embodiments, an energy delivery surface may preferably comprise a plurality of spaced electrodes 112. The power generating apparatus 101 as shown in FIG. 1 is operatively coupled to the plurality of electrodes by connector 103 so as to preferably allow the selective energizing of selected electrodes.

In many embodiments, the energy delivery surface comprises a plurality of electrodes 112 disposed about an expandable balloon 200, as shown in FIG. 3A, so as to define a plurality of remodeling zones in the target tissue when the balloon is expanded to come in contact with tissue such as that of a lumen.

Now referring to FIGS. 1 and 2, one exemplary embodiment of a catheter system inducing desirable temperature effects on tissue is shown. The catheter system includes a balloon catheter 108 having a catheter body 109 with a proximal end 107 and a distal end 111. Catheter body 109 is flexible and defines a catheter axis 113, and may include one or more lumens, such as a guidewire lumen 206 and an inflation lumen 201. Still further lumens may be provided if desired for other treatments or applications, such as perfusion, fluid delivery, imaging, or the like. Catheter 108 includes an inflatable balloon 200 adjacent distal end 111 and a housing 106 adjacent proximal end 107. Housing 106 includes a first connector 104 in communication with guidewire lumen 206 and a second connector 105 in fluid communication with inflation lumen 201. Inflation lumen 201 extends between balloon 200 and second connector 105. Both first and second connectors 104 and 105 may optionally comprise a standard connector, such as a LUER-LOC™ connector. A distal tip may include an integral tip valve to allow passage of guidewires, and the like.

The housing 106 may also accommodate an electrical connector 103, which may preferably include a plurality of electrical connections, each electrically coupled to electrodes 112 via conductors 203. This arrangement preferably allows the electrodes 112 to be easily energized, the electrodes often being energized by an enclosed controller and power source 101, which may preferably produce energy in the form of monopolar or bipolar RF energy, microwave energy, ultrasound energy, or other such suitable forms of energy. In one such embodiment, the electrical connector 103 is coupled to circuit 400 of FIG. 4 that in its most preferable form may produce RF energy in a manner that may allow energy to be selectively directed to electrodes 112 as shown in FIG. 3B. When monopolar RF energy is employed, patient ground may, for example, be provided by an external electrode or an electrode on catheter body 109.

Now referring to FIGS. 3B and 1, the electrodes 112 are preferably coupled with the surrounding tissue 300, such that energy may be transmitted between the electrodes 112A, 112B, 112C, 112D and the tissue 300 so as to preferably initiate a biological response. The balloon 200 will typically comprise distal end 111 of a balloon catheter 108, and the energy delivery surfaces, such as electrodes 112, on the balloon 200 will generally be energized using an energy source coupled to proximal end 107 of catheter 108. An energy conduit 203 may extend along a catheter body 109 between the proximal end 107 and balloon 200, with the energy conduit 203 often comprising an electrical conductor for applying RF energy or the like, a light conductor such as a fiber optic filament running along a lumen in the catheter body so as to conduct laser or other light energies, or the like.

As shown in FIG. 3B, electrodes 112 may preferably be positioned circumferentially around balloon 200. Energy 301, most preferably RF energy, may in the most preferred embodiment be directed to adjacent pairs of electrodes 112A and 112C, or 112A and 112D, or any combination of electrodes 112A-112D, treating both the healthy portion of tissue 303 and diseased portion of tissue 302 within the surrounding tissue 300. This arrangement preferably creates an energy path 301 that may deliver energy or heat (“tissue remodeling energy”) in particular treatment zones or segments to the tissue 300 between the electrode pairs 112A-112D (“remodeling zones”) having a volume between the electrode pairs 112A-112D at a specific depth. Using different combinations of electrode pairs 112A-112D may reduce or eliminate gaps between the remodeling zones by using overlapping pairs. Using electrode pairs 112A-112D with bipolar energy preferably may thereby provide improved performance compared to a monopolar approach. Diseased tissue 302 is known to have higher electrical resistivity than healthy tissue 303. By using pairs of electrodes 112 in a bipolar system, such as 112A and 112B, tissue remodeling energy may preferably pass through healthy tissue 303, diseased tissue 302, or a combination thereof such that remodeling zones may be created. Any number of electrodes 112 may be used in different patterns or arrays to create any number of remodeling zones. Power generator and control apparatus 101 may apply constant power, constant voltage, constant current, or modulate to produce a constant temperature, whichever has the most advantage for the type of tissue and the desired therapeutic response.

Balloon 200 is illustrated in more detail in FIG. 2. Balloon 200 generally includes a proximal portion 202 coupled to inflation lumen 201 and a distal portion 205 coupled to guidewire lumen 206. Balloon 200 expands radially when inflated with a fluid or a gas. In some embodiments, balloon 200 may be a low-pressure balloon pressurized to contact the tissue 300. In other embodiments, balloon 200 may an angioplasty balloon capable of higher pressure to both heat the tissue 300 and expand the tissue 300 lumen. Balloon 200 may comprise a compliant or non-compliant balloon having folds to facilitate reconfiguring the balloon from a radially expanded, inflated configuration to a low profile configuration, particularly for removal after use.

Electrodes 112 are mounted on a surface of balloon 200, with associated conductors 203 extending proximally from the electrodes 112. Electrodes 112 may be arranged in many different patterns or arrays on balloon 200. The system may be used for monopolar or bipolar application of energy. For delivery of monopolar energy, a ground electrode may be used either on the catheter 108 shaft or on the patient's skin, such as a ground electrode pad. For delivery of bipolar energy, adjacent electrodes 112 may be axially offset to allow bipolar energy to be directed between adjacent circumferential (axially offset) electrodes 112. In other embodiments, electrodes 112 may be arranged in bands around balloon 200 to allow bipolar energy to be directed between adjacent distal and proximal electrodes 112.

Tissue Sensing and Selective Delivery of Therapeutic Energy Dosage

In many embodiments electrodes 112 may be energized to assess and then selectively treat targeted tissue 300, 302, 303 to preferably achieve a therapeutic result. For example, tissue signature may be used to identify tissue treatment regions with the use of impedance measurements. Impedance measurements utilizing circumferentially spaced electrodes 112 within a lumen, such as those shown in FIG. 3B, may be used to analyze tissue 300, 302, 303. Impedance measurements between pairs of adjacent electrodes 112 (and/or between pairs of separated electrodes 112A-112D) may differ when the current path passes through diseased tissue 302, and when it passes through healthy tissues 303 of a luminal wall for example. Hence, impedance measurements between the electrodes 112 on either side of diseased tissue 302 may indicate a lesion, while measurements between other pairs of adjacent electrodes 112 may indicate healthy tissue 303. Other characterization, such as intravascular ultrasound, optical coherence tomography, or the like may be used to identify regions to be treated either in conjunction with, or as an alternate to, impedance measurements. In some instances, it may be desirable to obtain baseline measurements of the tissues 300, 302, 303 to be treated preferably to help differentiate adjacent tissues, as the tissue signatures and/or signature profiles may differ from person to person. Additionally, the tissue signatures and/or signature profile curves may be normalized to facilitate identification of the relevant slopes, offsets, and the like between different tissues. Any of the techniques disclosed in U.S. Patent Application No. 60/852,787, filed on Oct. 18, 2006, entitled “Tuned RF Energy and Electrical Tissue Characterization For Selective Treatment Of Target Tissues”, U.S. Provisional Application No. 60/921,973, filed on Apr. 4, 2007, entitled “Tuned RF Energy and Electrical Tissue Characterization For Selective Treatment Of Target Tissues”, the full disclosures of which are incorporated herein by reference, may be combined with the present invention.

The power generator and control apparatus 101 may be employed to selectively energize the electrodes 112 in a range of power from about 0.001 Watts to about 50 Watts, a preferred exemplary range of about 0.25 to 5 Watts average power for about 1 to about 180 seconds, or with about 4 to about 45 Joules. Higher energy treatments are done at lower powers and longer durations, such as about 0.5 Watts for about 90 seconds or about 0.25 Watts for about 180 seconds. Most treatments in the 2 to 4 Watt range are performed in about 1 to about 4 seconds. If using a wider electrode 112 spacing, it would be preferable to scale up the average power and duration of the treatment, in which case the average power could be higher than about 5 Watts, and the total energy could exceed about 45 Joules. Likewise, if using a shorter or smaller electrode pair 112A-112D, it would be preferable to scale the average power down, and the total energy could be less than about 4 Joules. The power and duration are calibrated to be less than enough to cause severe damage, and most preferably, particularly less than enough to ablate diseased tissue within a blood vessel.

Suitable power ranges for providing the desired heating of the target tissue, and/or for limiting of heating to collateral tissues, may depend at least in part on the time for which energy is applied, on the electrode 112 (or other energy transmitting surface) geometry, and the like. First, when applying the treatments described herein to tissues with electrodes, there may be a preferred load impedance range for the tissues within the circuit so as to avoid having to apply voltages and/or currents that are outside desirable ranges, particularly when applying powers within ranges described herein. Suitable load impedance ranges would generally be within a range from about 20 Ohms to about 4500 Ohms, more typically being in a range from about 40 Ohms to about 2250 Ohms, and preferably being in a range from about 50 to about 1000 Ohms.

The load impedance of the tissue within the circuit may depend on the characteristics of the tissue, and also for example on the geometry of electrodes that engage the tissue, as the electrode geometries and polarity influence the geometry of the tissue effectively included within the circuit. The tissue to which energy is directed may have a specific conductivity in a range from about 0.2 Siemens per meter to about 0.5 Siemens per meter. Different types of diseased tissues may have specific conductivities in different ranges, with some types of diseased tissues having specific conductivities in a range from about 0.2 Siemens per meter to about 0.35 Siemens per meter, while others fall within a range from about 0.35 Siemens per to about 0.5 Siemens per meter.

Desired power, energy, and time of the treatment are likewise inter-related, and may also be at least related with electrode 112 geometry. Speaking very generally, lower power treatments applied for long times tends to result in treatments with relatively higher total energies, while higher power treatments for shorter times tends to result in lower energy treatments. More specifically, at relatively low average power (1 W or less) the total energy delivery per treatment may range from about 8 to about 45 Joules. At higher power (more than 1 W), the total energy delivery per treatment may range from about 4 to about 15 Joules. If the electrode spacing were doubled, power may increase by four times. The power transmitted into the tissue can be calibrated and scaled to the particular electrode configuration, often in order to keep the power and energy density in a desirable range. Exemplary power ranges may be, for example, from about 1 to about 5 Watts. The duration for the lower power settings typically varies from about 1 to about 8 seconds. Very low power settings of less than about 1 Watt are also possible, using durations much longer than about 10 seconds.

It is also possible to scale the power settings significantly by varying the electrode 112 configuration. If, for instance, the inner edge-to-edge spacing of the electrodes 112 is increased, roughly 4 times the power may be applied because the volume of tissue becomes roughly 4 times larger. As such, electrode configurations different from the exemplary embodiments described herein could be used within a power range of about 4 to about 20 Watts. Shortening the electrodes 112, and thus shortening and reducing the volume of the remodeling zones, would also affect the magnitude of the power that is appropriate to apply to the tissue volume.

In order to quantify this complex set of relationships, and bound the space within which the exemplary apparatus can operate, an empirical relationship between safe values of several of these parameters may be generated and provided graphically, in table form, or by a mathematical relationships. An exemplary equation describing a particularly advantageous relationship is:

power=bx²Lt^−0.59

where b is a parameter in the range of 0.2 to 0.6, x is the inner edge-to-edge spacing of the electrodes 112 in millimeters, L is the length of the electrodes 112 in millimeters (and also the approximate length of the remodeling zone), the power is in Watts, and t is time in seconds. b has units of (Watts/mm³)*(seconds^0.59). Exemplary treatments in the range described by this equation include treatments such as 4 Watts for 2 seconds, 3 Watts for 3 seconds, 2 Watts for 4 seconds, and 1 Watt for 12 seconds.

Calibration of circuit 400 may be performed by taking three measurements at known circuit loads 404, most preferably, impedance Z_ρOis taken at load of about 1000Ω, impedance Z_ρSis taken at a load of about 50Ω, and impedance Z_ρLis taken at a load of about 150Ω, where the complex voltage and current measurements (800_V&Iof FIG. 8) at power generator and control apparatus 101 are used to calculate impedances Z_ρO, Z_ρS, and Z_ρL. The preferred method of calibration may allow for accurate real-time measurement of impedance before and during treatment of tissue such that impedance may provide a means for tissue characterization and treatment control as disclosed and described herein.

Calibration of apparatus 100 may further comprise the step of identifying an accessory attached to the apparatus by repeating calibration to ascertain the type of attached accessory based on its impedance characteristics. For example, in FIG. 1 where the attached accessory comprises catheter 108 further comprised of electrodes 112, the number of electrodes 112 present may be determined by multiplexed sensing of the number of electrode circuits (such as electrodes 112 and conductors 203 as shown in FIG. 2) within the catheter 108 operably attached by connector 103 to power generator and control apparatus 102. Referring once again to FIGS. 1, 4, 8, and 16, after calibration of power generator circuit 400 without accessory 100′ (typically catheter 108), the catheter can be attached to the power generator circuit 1603 and three impedance measurements can again be taken of the overall apparatus 100.

A number of advantages may be gained by preferably automatically reperforming calibration. For example, by having an entire apparatus assembly 100 calibrated, rather than a single subcomponent such as the various elements of circuit 400, the impedance measurements taken at load 404 may remain an accurate indicator for tissue characterization and power control irrespective of the attached accessory. Further, the sensed configuration of an attached accessory may correspond to a programmed treatment routine such that the dependencies of assorted configurations of electrodes 112 may correspond to the preferred duration and energy delivery parameters disclosed and described herein. Even further, preprogrammed recognition of attached accessories prevents the improper use of an accessory or the use of an incompatible attachment. Even further, the ability to detect the type of attached accessory may allow for a robust and simple accessory identification method that avoids complications associated with other identification methods such as radio frequency identification that may degrade during sterilization or interfere with the operation of other equipment. Moreover, a self-identification method may reduce or eliminate the need for user commands thereby improving ease of use and minimizing issues such as language barriers between user and apparatus. Additionally, the use of a graphical user interface 102 may be used as a further means to eliminate or reduce language dependencies and increase ease of use.

In many embodiments the power generation and control apparatus 101 may be programmed to operate within a range of impedance values measured at the power delivery target 404 such that above or below set limits the system may automatically shut down. For example, the apparatus 101 may be programmed to operate over a range of load impedance from about 5 Ohms to about 1000 Ohms, having a most preferred range of about 50 Ohms to about 500 Ohms, wherein the low end of the range may be suggestive of tissue that may be healthy or responsive to tissue, and the high end of the range may be suggestive of poor electrical contact or destruction of tissue. The programmed impedance limits may provide the advantage of a further safeguard in avoiding uncontrolled application of energy to locations in excess of desired dosage.

FIGS. 10-13 respectively show current, impedance, voltage, phase angle, and electrode power response in a typical tissue treatment employing gentle heating as controlled and delivered by the apparatus assembly of FIG. 1. In FIG. 13, the measured power at the target is shown in comparison to the power output at the generator.

Embodiments of the vascular treatment devices, systems, and methods described herein may be used to treat atherosclerotic disease by gentle heating in combination with gentle or standard dilation. For example, an angioplasty balloon catheter structure 108 having electrodes 112 disposed thereon might apply electrical potentials to the vessel wall before, during, and/or after dilation, optionally in combination with dilation pressures which are at or significantly lower than standard, unheated angioplasty dilation pressures. Where balloon 200 inflation pressures of about 10 to about 16 atmospheres may, for example, be appropriate for standard angioplasty dilation of a particular lesion, modified dilation treatments combined with appropriate electrical potentials, through flexible circuit electrodes 112, 203 on balloon 200, electrodes 112 deposited directly on the balloon structure 200, or the like, described herein may employ from about 10 to about 16 atmospheres or may be effected with pressures of about 6 atmospheres or less, and possibly as low as about 1 to about 2 atmospheres. Such moderate dilations pressures may, or may not, be combined with one or more aspects of the tissue characterization, tuned energy, eccentric treatments, and other treatment aspects described herein for treatment of diseases of the vasculature.

In many embodiments, gentle heating energy added before, during, and/or after dilation of a blood vessel may increase dilation effectiveness while lowering complications. In some embodiments, such controlled heating with balloon 200 may exhibit a reduction in recoil, providing at least some of the benefits of a stent-like expansion without the disadvantages of an implant. Benefits of the heating may be enhanced, and/or complications inhibited, by limiting heating of the vessel adventitial layer below a deleterious response threshold. In many cases, such heating of the vessel intima and/or media may be provided using heating times of less than about 10 seconds, often being less than about 3 (or even 2) seconds. In other cases, very low power may be used for longer durations. Efficient coupling of the energy 301 to the target tissue 300, 302, 303 by matching the driving potential of the circuit to the target tissue phase angle may enhance desirable heating efficiency, effectively maximizing the area under the electrical power curve. The matching of the phase angle need not be absolute, and while complete phase matching to a characterized target tissue may have benefits, alternative systems may pre-set appropriate potentials to substantially match typical target tissues; though the actual phase angles may not be matched precisely, heating localization within the target tissues may be significantly better than using a standard power form.

Remodeling may involve the application of energy, most preferably in the form of RF, but also microwave and/or ultrasound energy to electrodes 112, and the like. This energy will be controlled so as to limit a temperature of target and/or collateral tissues, for example, limiting the heating of a fibrous cap of a vulnerable plaque or the intimal layer of an artery structure.

In some embodiments, the surface tissue temperature range is from about 50° C. to about 90° C. For gentle heating, the tissue surface temperature may range from about 50° C. to about 65° C., while for more aggressive heating, the surface tissue temperature may range from about 65° C. to about 90° C. Limiting heating of a lipid-rich pool of a vulnerable plaque sufficiently to induce melting of the lipid pool while inhibiting heating of other tissues, such as an intimal layer or fibrous cap, to less than a tissue surface temperature in a range from about 50° C. to about 65° C., such that the bulk tissue temperature remains mostly below about 50° C. to about 55° C. may inhibit an immune response that might otherwise lead to restenosis, or the like. Relatively mild surface temperatures between about 50° C. and about 65° C. may be sufficient to denature and break protein bonds during treatment, immediately after treatment, and/or more than one hour, more than one day, more than one week, or even more than one month after the treatment through a healing response of the tissue to the treatment so as to provide a bigger vessel lumen and improved blood flow.

While the methods and devices described herein are not selective in tissue treatment of the blood vessels, the apparatus 100 can be used for treatment of both concentric and eccentric atherosclerosis, because atherosclerosis may be eccentric relative to an axis of the blood vessel over 50% of the time, and possibly in as much as (or even more than) 75% of cases.

Hence, remodeling of atherosclerotic materials may comprise shrinkage, melting, and the like, of atherosclerotic and other plaques. Atherosclerotic material within the layers of an artery may be denatured, melted and/or the treatment may involve a shrinking of atherosclerotic materials and/or delivery of bioactives within the artery layers so as to improve blood flow. The invention may also provide particular advantages for treatment of vulnerable plaques or blood vessels in which vulnerable plaque is a concern, which may comprise eccentric lesions. The invention will also find applications for mild heating of the cap structure to induce thickening of the cap and make the plaque less vulnerable to rupture, and/or heating of the lipid-rich pool of the vulnerable plaque so as to remodel, denature, melt, shrink, and/or redistribute the lipid-rich pool.

Controlled Application of Energy to Achieve Substantially Uniform Bulk Temperature

Now referring to FIGS. 14A-15B, the controlled delivery of energy as a dosage may preferably be used to obtain a substantially uniform temperature distribution in bulk tissue by the selective distributed delivery of energy. Most preferably, tissue may be heated within a range of about 50° C. to about 70° C. to achieve a temperature preferably high enough to denature proteins and promote a healing response while avoiding tissue damage that may be caused at higher temperatures. Regulation of tissue temperature may be accomplished through direct temperature measurement using means such as a thermocouple, thermister, and the like. However, it may be advantageous to simplify the apparatus and to preferably avoid potential increases in device profile caused by the inclusion of wires or other sensing hardware into an intraluminal device. Because the present invention possesses the capability to deliver precise energy dosage and the capability to measure real-time changes in impedance at the point of power delivery, a uniform temperature distribution may be also achieved through these means.

In one preferred embodiment, tissue impedance may be used to infer tissue temperature conditions. The change in impedance as a function of time, or the derivative of the impedance slope (dz/dt), may be used to sense change in tissue temperature. Specifically, increase in impedance suggests tissue cooling given that tissue conductance is reduced as tissue cools. Conversely, decrease in impedance suggests tissue heating given that tissue conductance increases as tissue heats. Therefore, substantially constant tissue impedance, or dz/dt about equal to zero, may be used as a means to obtain a generally uniform temperature distribution through the sensing of impedance at the point of power delivery.

A distributed delivery of energy may be preferably employed to further aid in obtaining uniformity in bulk temperature. For example, electrodes 112A-L may be distributed about the circumference of a balloon. Electrodes 112A-L may be powered in a bipolar mode wherein alternate electrode pairs are powered such that in a first sequential application of energy every other electrode pair is powered at a discrete energy level for a discrete period of time. In a second sequential application of energy the electrode pairs not fired in the first sequential application of energy are powered. The configuration and ordering of power to electrode pairs to accomplish a particular temperature, for example 50° C., or 60° C., or 70° C., may be determined empirically. The duration of energy delivery in the form of sequential dosage to preferably maintain a substantially uniform temperature in the bulk tissue may then be controlled through tissue impedance measurement.

Although any variety of time for power, time between power, space between electrodes powered, and total energy delivered may be employed based on the specific nature of tissue to be heated, one preferred embodiment shown in FIG. 14A shows a substantially uniform temperature distribution by sequentially powering every other electrode pair for about 1.5 seconds at about 4 Watts, followed by sequentially powering the previously unpowered electrodes for about 1 second at about 4 Watts. The benefit of spaced sequential firing is that tissue may naturally heat, hold, and begin to cool such that high concentrations of heat are preferably avoided as compared to applying power without selective distribution. Once the initial power dosage is delivered, additional power may be applied as regulated trough tissue impedance measurement. In an alternate exemplary embodiment shown in FIG. 14B, power is delivered in the same sequential manner as described for FIG. 14A, however, the second sequential application of power follows a pause of about 30 seconds and the duration of the second sequential application of power may be increased to about 1.5 seconds.

In another exemplary embodiment, shown in FIGS. 15A-B, the use of accumulated damage theory, such as that described by the Arrhenius equation, may be employed to numerically predict energy dosage such that accumulated tissue temperature effects may be used to build a power dosage routine. A first sequential power delivery between every other electrode pair at about 4 Watts for about 5 seconds may be followed by a second sequential power delivery to the previously unpowered electrode pairs wherein the power level and time duration for each electrode pair in the second sequence may vary by position such that the accumulated heating and cooling of tissue preferably is accounted for such that a substantially uniform temperature distribution may be achieved. For example, the ordered second energizing sequence of electrode pairs may be about 4 Watts for about 0.45 seconds for the first electrode pair in the sequence, about 2.6 Watts for about 0.65 seconds for the second electrode pair in the sequence, about 1.8 Watts for about 1.15 seconds at the third pair, about 1.5 Watts for about 1.65 seconds at the fourth pair, about 1.3 Watts for about 3.15 seconds at the fifth pair, and about 1.1 Watts for about 5 seconds. In this example, the accumulated effect would preferably result in a tissue temperature of about 60° C. using a balloon with 12 electrodes distributed about the outer circumference of the balloon.

The use of accumulated damage theory may be tailored to specific types of tissue based on characterized tissue response curves such that power dosage routines may be developed specifically for accomplishing a certain temperature in a certain tissue type.

Additionally, whether using a damage accumulation model, or tissue impedance measurement to maintain bulk tissue temperature at a substantially uniform distribution, the energy dosage may vary, in part, based on electrode configuration as previously described herein.

Application of Energy to Modify Nerve Activity

In yet another exemplary embodiment of the present invention, the ability to deliver energy in a targeted dosage may be used for nerve tissue in order to achieve beneficial biologic responses. For example, chronic pain, urologic dysfunction, hypertension, and a wide variety of other persistent conditions are known to be affected through the operation of nervous tissue. For example, it is known that chronic hypertension that may not be responsive to medication may be improved or eliminated by disabling excessive nerve activity proximate to the renal arteries. It is also known that nervous tissue does not naturally possess regenerative characteristics. Therefore it may be possible to beneficially affect excessive nerve activity by disrupting the conductive pathway of the nervous tissue. When disrupting nerve conductive pathways, it is particularly advantageous to avoid damage to neighboring nerves or organ tissue. The ability to direct and control energy dosage is well-suited to the treatment of nerve tissue. Whether in a heating or ablating energy dosage, the precise control of energy delivery as described and disclosed herein may be directed to the nerve tissue. Moreover, directed application of energy may suffice to target a nerve without the need be in exact contact as would be required when using a typical ablation probe. For example, eccentric heating may be applied at a temperature high enough to denature nerve tissue without causing ablation and without requiring the piercing of luminal tissue. However, it may also be preferable to configure the energy delivery surface of the present invention to pierce tissue and deliver ablating energy similar to an ablation probe with the exact energy dosage being controlled by the power control and generation apparatus 101.

Referring again to the example of renal hypertension involving the reduction of excessive nerve activity, FIG. 3B may be used to describe a non-piercing, non-ablating way to direct energy to affect nerve activity. Nerve tissue may be located in some location in tissue 300, 302, 303 surrounding the lumen of the renal artery. Electrodes 112 on balloon 200 may be powered to deliver energy 301 in the known direction of a nerve to be affected, the depth of energy penetration being a function of energy dosage. Moreover, empirical analysis may be used to determine the impedance characteristics of nervous tissue such that apparatus 101 may be used to first characterize and then treat tissue in a targeted manner as disclosed and described herein. The delivery and regulation of energy may further involve accumulated damage modeling as well.

While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modification, adaptations, and changes may be employed.

Claims

1. A power generating apparatus for treatment of tissue having a circuit comprising: a direct digital synthesizer (DDS) operatively coupled to a power amplifier;a power output set point controller providing a signal;a peak effective power sensor receiving voltage and current feedback measured during delivery of power from the circuit to a power delivery target, the peak effective power sensor providing a signal based on the feedback; anda PID controller, operatively coupled to receive the signals from the power output set point controller and the peak effective power sensor, and operatively coupled to direct a modulating voltage signal to the power amplifier such that output of power from the circuit is maintained within a range about a power output set point in response to the signal from the peak effective power sensor, wherein the output of power from the circuit is continuously maintained during a treatment period,wherein the power amplifier is comprised of a variable gain amplifier and a linear power amplifier operatively coupled in series.
2. The power generating apparatus of claim 1 wherein a digital-to-analog converter is coupled between the DDS and power amplifier.
3. The power generating apparatus of claim 1 wherein energy output is RF energy.
4. The power generating apparatus of claim 1 wherein the power delivery target is comprised of tissue.
5. The power generating apparatus of claim 1 wherein the DDS, power output set point controller, and peak effective power sensor comprise a field programmable gate array.
6. The power generating apparatus of claim 1 wherein the power amplifier is comprised of a linear power amplifier whose maximum output voltage is controlled by the current flowing in the power amplifier.
7. The power generating apparatus of claim 6 wherein output voltage from the linear power amplifier to the power delivery target during use comprises RF output voltage having a maximum available output limit over a range of load impedances of about 50 Ohm to about 500 Ohms.
8. The power generating apparatus of claim 6 wherein the maximum output voltage from the linear power amplifier limits the power dissipation within the power amplifier.
9. The power generating apparatus of claim 6 wherein the linear power amplifier controls the maximum output voltage using switched mode technology.
10. The power generating apparatus of claim 1 wherein the modulating voltage signal from the PID controller is received by the variable gain amplifier.
11. The power generating apparatus of claim 1 wherein the peak effective power sensor comprises a DDS, a current circuit further comprising square root and inverse tangent gates in parallel, and a voltage circuit further comprising square root and inverse tangent gates in parallel.
12. The power generating apparatus of claim 11 wherein the DDS of the peak effective power sensor has a voltage output with a low-pass filter, and a current output with a low-pass filter.
13. The power generating apparatus of claim 11 wherein output of the inverse tangent gates for the current circuit and the voltage circuit are operatively coupled to pass through a cosine gate.
14. The power generating apparatus of claim 1 wherein the voltage and current feedback from the power delivery target to the peak effective power sensor each comprise in-phase and quadrature signal components.
15. The power generating apparatus of claim 1 wherein the signal from the peak effective power sensor represents the effective power output of the circuit at the power delivery target.
16. The power generating apparatus of claim 1 wherein the power output set point is about 0.001 Watts to about 50 Watts.
17. The power generating apparatus of claim 1 wherein the power output modulates about the set point by a maximum of about ±20%.
18. The power generating apparatus of claim 1 wherein the power output modulates about the set point by a maximum of about ±10%.
19. The power generating apparatus of claim 1 wherein the power output modulates about the set point by a maximum of about ±5%.
20. The power generating apparatus of claim 1 wherein the power output modulates about the set point by a maximum of about ±2%.
21. A power generating apparatus for treatment of tissue comprising: a DDS operatively coupled to a RF power amplifier;a RF power output set point controller providing a signal;a peak effective RF power sensor receiving voltage and current feedback measured at a RF power delivery target during RF power delivery to the power delivery target, the peak effective RF power sensor providing a signal based on the feedback; anda controller, operatively coupled to receive the signals from the RF power output set point controller and the peak effective RF power sensor, and operatively coupled to direct a modulating voltage signal to the RF power amplifier such that the output of RF power from the circuit is maintained within a range about the RF power output set point in response to the signal provided by the peak effective RF power sensor, wherein the output of RF power from the circuit is continuously maintained during a treatment period,wherein the power amplifier is comprised of a variable gain amplifier and a linear power amplifier operatively coupled in series.
22. A power generating and control apparatus for eccentric remodeling treatment of tissue about a lumen, the apparatus comprising: a DDS operatively coupled to a RF power amplifier;a RF power output set point controller providing a signal;a peak effective RF power sensor receiving voltage and current feedback measured at the tissue during RF power delivery about the circumference of the lumen, the peak effective RF power sensor providing a signal based on the feedback; anda controller, operatively coupled to receive the signals from the RF power output set point controller and the peak effective RF power sensor, and operatively coupled to direct a modulating voltage signal to the RF power amplifier such that the output of RF power from the circuit is maintained within a therapeutic tissue remodeling range about the RF power output set point in response to the signal provided by the peak effective RF power sensor, wherein the output of RF power from the circuit is continuously maintained during a treatment period,wherein the power amplifier is comprised of a variable gain amplifier and a linear power amplifier operatively coupled in series.
23. A power generating apparatus for treatment of a target tissue, the power generating apparatus comprising: a frequency synthesizer generating a frequency signal;a power amplifier operatively coupling the frequency synthesizer to a power output, the output coupleable to the target tissue;a power sensor configured to receive voltage and current feedback from the target tissue during power output delivery to the target tissue and to output a signal based on the voltage and current feedback; anda controller coupling the power sensor to the power amplifier, the controller having an input for receiving a power set point and transmitting, in response to the power set point and the signal from the power sensor, a modulating signal to the power amplifier such that power output from the power amplifier to the target tissue per the frequency signal is maintained within a range about the power set point, wherein the output of power from the power amplifier is continuously maintained during a treatment period,wherein the power amplifier is comprised of a variable gain amplifier and a linear power amplifier operatively coupled in series.
24. The power generating apparatus of claim 23 wherein the frequency synthesizer comprises a digital frequency synthesizer, and wherein a digital-to-analog converter couples the frequency synthesizer to the power amplifier.
25. The power generating apparatus of claim 23 wherein energy output to the target comprises RF energy.

CROSS-REFERENCES TO RELATED APPLICATIONS

The present application claims the benefit under 35 USC 119(e) of U.S. Provisional Application No. 61/342,191 filed Apr. 9, 2010; the full disclosure of which is incorporated herein by reference in its entirety for all purposes. The subject matter of this application is related to that of U.S. patent application Ser. No. 11/392,231, filed on Mar. 28, 2006, entitled “Tuned RF Energy for Selective Treatment of Atheroma and Other Target Tissues and/or Structures”; U.S. patent application Ser. No. 10/938,138, filed on Sep. 10, 2004, entitled “Selectable Eccentric Remodeling and/or Ablation of Atherosclerotic Material”; U.S. Provisional Application No. 60/852,787, filed on Oct. 18, 2006, entitled “Tuned RF Energy and Electrical Tissue Characterization For Selective Treatment Of Target Tissues”; U.S. Provisional Application No. 60/921,973, filed on Apr. 4, 2007, entitled “Tuned RF Energy and Electrical Tissue Characterization For Selective Treatment Of Target Tissues”; U.S. patent application Ser. No. 11/975,651, filed on Oct. 18, 2007, entitled “Tuned RF Energy and Electrical Tissue Characterization For Selective Treatment Of Target Tissues”; U.S. patent application Ser. No. 12/617,519, filed on Nov. 12, 2009, entitled “Selective Accumulation of Energy With or Without Knowledge of Tissue Topography”; U.S. patent application Ser. No. 11/975,474, filed on Oct. 18, 2007, entitled “Inducing Desirable Temperature Effects on Body Tissue”; U.S. patent application Ser. No. 11/975,383, filed on Oct. 18, 2007, entitled “System for Inducing Desirable Temperature Effects On Body Tissue”; U.S. patent application Ser. No. 12/616,720, filed on Nov. 13, 2009, entitled “Selective Drug Delivery in a Lumen”; U.S. application Ser. No. 12/564,268, filed on Sep. 22, 2009, entitled “Inducing Desirable Temperature Effects on Body Tissue Using Alternate Energy Sources”; and U.S. Provisional Application 61/177,744, filed on May 13, 2009, entitled “Directional Delivery of Energy and Bioactives”, the full disclosures of which are incorporated herein by reference.

US Referenced Citations (1558)

Number	Name	Date	Kind
164184	Kiddee	Jun 1875	A
1167014	O'Brien	Jan 1914	A
2505358	Gusberg et al.	Apr 1950	A
2701559	Cooper	Feb 1955	A
3108593	Glassman	Oct 1963	A
3108594	Glassman	Oct 1963	A
3540431	Mobin-Uddin	Nov 1970	A
3952747	Kimmell, Jr.	Apr 1976	A
3996938	Clark, III	Dec 1976	A
4046150	Schwartz et al.	Sep 1977	A
4290427	Chin	Sep 1981	A
4402686	Medel	Sep 1983	A
4416277	Newton et al.	Nov 1983	A
4483341	Witteles et al.	Nov 1984	A
4574804	Kurwa	Mar 1986	A
4587975	Salo et al.	May 1986	A
4649936	Ungar et al.	Mar 1987	A
4682596	Bales et al.	Jul 1987	A
4709698	Johnston et al.	Dec 1987	A
4765331	Petruzzi et al.	Aug 1988	A
4770653	Shturman	Sep 1988	A
4784132	Fox et al.	Nov 1988	A
4784162	Ricks et al.	Nov 1988	A
4785806	Deckelbaum	Nov 1988	A
4788975	Shturman et al.	Dec 1988	A
4790310	Ginsburg et al.	Dec 1988	A
4799479	Spears	Jan 1989	A
4823791	D'Amelio et al.	Apr 1989	A
4830003	Wolff et al.	May 1989	A
4849484	Heard	Jul 1989	A
4862886	Clarke et al.	Sep 1989	A
4887605	Angelsen et al.	Dec 1989	A
4907589	Cosman	Mar 1990	A
4920979	Bullara	May 1990	A
4938766	Jarvik	Jul 1990	A
4955377	Lenno et al.	Sep 1990	A
4976711	Parins et al.	Dec 1990	A
5034010	Kittrell et al.	Jul 1991	A
5052402	Bencini et al.	Oct 1991	A
5053033	Clarke	Oct 1991	A
5071424	Reger	Dec 1991	A
5074871	Groshong	Dec 1991	A
5098429	Sterzer	Mar 1992	A
5098431	Rydell	Mar 1992	A
5102402	Dror et al.	Apr 1992	A
RE33925	Bales et al.	May 1992	E
5109859	Jenkins	May 1992	A
5125928	Parins et al.	Jun 1992	A
5129396	Rosen et al.	Jul 1992	A
5139496	Hed	Aug 1992	A
5143836	Hartman et al.	Sep 1992	A
5156151	Imran	Oct 1992	A
5156610	Reger	Oct 1992	A
5158564	Schnepp-Pesch et al.	Oct 1992	A
5170802	Mehra	Dec 1992	A
5178620	Eggers et al.	Jan 1993	A
5178625	Groshong	Jan 1993	A
5190540	Lee	Mar 1993	A
5191883	Lennox et al.	Mar 1993	A
5211651	Reger et al.	May 1993	A
5234407	Teirstein et al.	Aug 1993	A
5242441	Avitall	Sep 1993	A
5251634	Weinberg et al.	Oct 1993	A
5254098	Ulrich et al.	Oct 1993	A
5255679	Imran	Oct 1993	A
5263493	Avitall	Nov 1993	A
5267954	Nita et al.	Dec 1993	A
5277201	Stern	Jan 1994	A
5282484	Reger	Feb 1994	A
5286254	Shapland et al.	Feb 1994	A
5295484	Marcus	Mar 1994	A
5297564	Love et al.	Mar 1994	A
5300068	Rosar et al.	Apr 1994	A
5301683	Durkan	Apr 1994	A
5304115	Pflueger et al.	Apr 1994	A
5304121	Sahatjian	Apr 1994	A
5304171	Gregory et al.	Apr 1994	A
5304173	Kittrell et al.	Apr 1994	A
5306250	March et al.	Apr 1994	A
5312328	Nita et al.	May 1994	A
5314466	Stern et al.	May 1994	A
5322064	Lundquist	Jun 1994	A
5324255	Passafaro et al.	Jun 1994	A
5326341	Lew et al.	Jul 1994	A
5326342	Pflueger et al.	Jul 1994	A
5330518	Neilson et al.	Jul 1994	A
5333614	Feiring	Aug 1994	A
5342292	Nita et al.	Aug 1994	A
5344395	Whalen et al.	Sep 1994	A
5345936	Pomeranz et al.	Sep 1994	A
5364392	Warner et al.	Nov 1994	A
5365172	Hrovat et al.	Nov 1994	A
5368557	Nita et al.	Nov 1994	A
5368558	Nita et al.	Nov 1994	A
5380274	Nita et al.	Jan 1995	A
5380319	Saito et al.	Jan 1995	A
5382228	Nita et al.	Jan 1995	A
5383874	Jackson et al.	Jan 1995	A
5383917	Desai et al.	Jan 1995	A
5397301	Pflueger et al.	Mar 1995	A
5397339	Desai	Mar 1995	A
5401272	Perkins et al.	Mar 1995	A
5403311	Abele et al.	Apr 1995	A
5405318	Nita et al.	Apr 1995	A
5405346	Grundy et al.	Apr 1995	A
5409000	Imran	Apr 1995	A
5417672	Nita et al.	May 1995	A
5419767	Eggers et al.	May 1995	A
5427118	Nita et al.	Jun 1995	A
5432876	Appeldorn et al.	Jul 1995	A
5441498	Perkins et al.	Aug 1995	A
5447509	Mills et al.	Sep 1995	A
5451207	Yock et al.	Sep 1995	A
5453091	Taylor et al.	Sep 1995	A
5454788	Walker et al.	Oct 1995	A
5454809	Janssen	Oct 1995	A
5455029	Hartman et al.	Oct 1995	A
5456682	Edwards et al.	Oct 1995	A
5457042	Hartman et al.	Oct 1995	A
5471982	Edwards et al.	Dec 1995	A
5474530	Passafaro et al.	Dec 1995	A
5478351	Meade et al.	Dec 1995	A
5496311	Abele et al.	Mar 1996	A
5496312	Klicek	Mar 1996	A
5498261	Strul	Mar 1996	A
5505201	Grill et al.	Apr 1996	A
5505730	Edwards	Apr 1996	A
5507744	Tay et al.	Apr 1996	A
5522873	Jackman et al.	Jun 1996	A
5531520	Grimson et al.	Jul 1996	A
5540656	Pflueger et al.	Jul 1996	A
5540679	Fram et al.	Jul 1996	A
5540681	Strul et al.	Jul 1996	A
5542917	Nita et al.	Aug 1996	A
5545161	Imran	Aug 1996	A
5562100	Kittrell	Oct 1996	A
5571122	Kelly et al.	Nov 1996	A
5571151	Gregory	Nov 1996	A
5573531	Gregory	Nov 1996	A
5573533	Strul	Nov 1996	A
5584831	McKay	Dec 1996	A
5584872	Lafontaine et al.	Dec 1996	A
5588962	Nicholas et al.	Dec 1996	A
5599346	Edwards et al.	Feb 1997	A
5601526	Chapelon et al.	Feb 1997	A
5609606	O'Boyle	Mar 1997	A
5626576	Janssen	May 1997	A
5630837	Crowley	May 1997	A
5637090	McGee et al.	Jun 1997	A
5643255	Organ	Jul 1997	A
5643297	Nordgren et al.	Jul 1997	A
5647847	Lafontaine et al.	Jul 1997	A
5649923	Gregory et al.	Jul 1997	A
5651780	Jackson et al.	Jul 1997	A
5653684	Laptewicz et al.	Aug 1997	A
5662671	Barbut et al.	Sep 1997	A
5665062	Houser	Sep 1997	A
5665098	Kelly et al.	Sep 1997	A
5666964	Meilus	Sep 1997	A
5667490	Keith et al.	Sep 1997	A
5672174	Gough et al.	Sep 1997	A
5676693	Lafontaine	Oct 1997	A
5678296	Fleischhacker et al.	Oct 1997	A
5681282	Eggers	Oct 1997	A
RE35656	Feinberg	Nov 1997	E
5688266	Edwards et al.	Nov 1997	A
5693015	Walker et al.	Dec 1997	A
5693029	Leonhardt	Dec 1997	A
5693043	Kittrell et al.	Dec 1997	A
5693082	Warner et al.	Dec 1997	A
5695504	Gifford et al.	Dec 1997	A
5697369	Long, Jr. et al.	Dec 1997	A
5697909	Eggers et al.	Dec 1997	A
5702386	Stern et al.	Dec 1997	A
5702433	Taylor et al.	Dec 1997	A
5706809	Littmann et al.	Jan 1998	A
5713942	Stern et al.	Feb 1998	A
5715819	Svenson et al.	Feb 1998	A
5735846	Panescu et al.	Apr 1998	A
5741214	Ouchi et al.	Apr 1998	A
5741248	Stern et al.	Apr 1998	A
5741249	Moss et al.	Apr 1998	A
5743903	Stern et al.	Apr 1998	A
5748347	Erickson	May 1998	A
5749914	Janssen	May 1998	A
5755682	Knudson et al.	May 1998	A
5755715	Stern et al.	May 1998	A
5755753	Knowlton	May 1998	A
5769847	Panescu et al.	Jun 1998	A
5769880	Truckai et al.	Jun 1998	A
5775338	Hastings	Jul 1998	A
5776174	Van Tassel	Jul 1998	A
5779698	Clayman et al.	Jul 1998	A
5782760	Schaer	Jul 1998	A
5785702	Murphy-Chutorian et al.	Jul 1998	A
5792105	Lin et al.	Aug 1998	A
5797849	Vesely et al.	Aug 1998	A
5797903	Swanson et al.	Aug 1998	A
5800484	Gough et al.	Sep 1998	A
5800494	Campbell et al.	Sep 1998	A
5807306	Shapland et al.	Sep 1998	A
5810802	Panescu et al.	Sep 1998	A
5810803	Moss et al.	Sep 1998	A
5810810	Tay et al.	Sep 1998	A
5817092	Behl	Oct 1998	A
5817113	Gifford et al.	Oct 1998	A
5817144	Gregory	Oct 1998	A
5823956	Roth et al.	Oct 1998	A
5827203	Nita	Oct 1998	A
5827268	Laufer	Oct 1998	A
5829447	Stevens et al.	Nov 1998	A
5830213	Panescu et al.	Nov 1998	A
5830222	Makower	Nov 1998	A
5832228	Holden et al.	Nov 1998	A
5833593	Liprie	Nov 1998	A
5836874	Swanson et al.	Nov 1998	A
5836943	Miller, III	Nov 1998	A
5840076	Swanson et al.	Nov 1998	A
5843016	Lugnani et al.	Dec 1998	A
5846238	Jackson et al.	Dec 1998	A
5846239	Swanson et al.	Dec 1998	A
5846245	McCarthy et al.	Dec 1998	A
5848969	Panescu et al.	Dec 1998	A
5853411	Whayne et al.	Dec 1998	A
5855614	Stevens et al.	Jan 1999	A
5860974	Abele	Jan 1999	A
5865801	Houser	Feb 1999	A
5868735	Lafontaine et al.	Feb 1999	A
5868736	Swanson et al.	Feb 1999	A
5869127	Zhong	Feb 1999	A
5871483	Jackson et al.	Feb 1999	A
5871524	Knowlton	Feb 1999	A
5875782	Ferrari et al.	Mar 1999	A
5876369	Houser	Mar 1999	A
5876374	Alba et al.	Mar 1999	A
5876397	Edelman et al.	Mar 1999	A
5879348	Owens et al.	Mar 1999	A
5891114	Chien et al.	Apr 1999	A
5891135	Jackson et al.	Apr 1999	A
5891136	McGee et al.	Apr 1999	A
5891138	Tu et al.	Apr 1999	A
5895378	Nita	Apr 1999	A
5897552	Edwards et al.	Apr 1999	A
5902328	Lafontaine et al.	May 1999	A
5904651	Swanson et al.	May 1999	A
5904667	Falwell et al.	May 1999	A
5904697	Gifford et al.	May 1999	A
5904709	Arndt et al.	May 1999	A
5906614	Stern et al.	May 1999	A
5906623	Peterson	May 1999	A
5906636	Casscells, III et al.	May 1999	A
5916192	Nita et al.	Jun 1999	A
5916227	Keith et al.	Jun 1999	A
5916239	Geddes et al.	Jun 1999	A
5919219	Knowlton	Jul 1999	A
5924424	Stevens et al.	Jul 1999	A
5925038	Panescu et al.	Jul 1999	A
5934284	Plaia et al.	Aug 1999	A
5935063	Nguyen	Aug 1999	A
5938670	Keith et al.	Aug 1999	A
5947977	Slepian et al.	Sep 1999	A
5948011	Knowlton	Sep 1999	A
5951494	Wang et al.	Sep 1999	A
5951539	Nita et al.	Sep 1999	A
5954717	Behl et al.	Sep 1999	A
5957882	Nita et al.	Sep 1999	A
5957941	Ream et al.	Sep 1999	A
5957969	Warner et al.	Sep 1999	A
5961513	Swanson et al.	Oct 1999	A
5964757	Ponzi et al.	Oct 1999	A
5967976	Larsen et al.	Oct 1999	A
5967978	Littmann et al.	Oct 1999	A
5967984	Chu et al.	Oct 1999	A
5971975	Mills et al.	Oct 1999	A
5971980	Sherman	Oct 1999	A
5972026	Laufer et al.	Oct 1999	A
5980563	Tu et al.	Nov 1999	A
5989208	Nita et al.	Nov 1999	A
5989284	Laufer	Nov 1999	A
5993462	Pomeranz et al.	Nov 1999	A
5997497	Nita et al.	Dec 1999	A
5999678	Murphy-Chutorian et al.	Dec 1999	A
6004269	Crowley et al.	Dec 1999	A
6004316	Laufer et al.	Dec 1999	A
6007514	Nita	Dec 1999	A
6010522	Barbut et al.	Jan 2000	A
6013033	Berger et al.	Jan 2000	A
6014590	Whayne et al.	Jan 2000	A
6019757	Scheldrup	Feb 2000	A
6022309	Celliers et al.	Feb 2000	A
6024740	Lesh et al.	Feb 2000	A
6030611	Gorecki et al.	Feb 2000	A
6032675	Rubinsky	Mar 2000	A
6033357	Ciezki et al.	Mar 2000	A
6033397	Laufer et al.	Mar 2000	A
6033398	Farley et al.	Mar 2000	A
6033399	Gines	Mar 2000	A
6036687	Laufer et al.	Mar 2000	A
6036689	Tu et al.	Mar 2000	A
6041260	Stern et al.	Mar 2000	A
6050994	Sherman	Apr 2000	A
6056744	Edwards	May 2000	A
6056746	Goble et al.	May 2000	A
6063085	Tay et al.	May 2000	A
6066096	Smith et al.	May 2000	A
6066139	Ryan et al.	May 2000	A
6068638	Makower	May 2000	A
6068653	LaFontaine	May 2000	A
6071277	Farley et al.	Jun 2000	A
6071278	Panescu et al.	Jun 2000	A
6078839	Carson	Jun 2000	A
6079414	Roth	Jun 2000	A
6080171	Keith et al.	Jun 2000	A
6081749	Ingle et al.	Jun 2000	A
6083159	Driscoll et al.	Jul 2000	A
6086581	Reynolds et al.	Jul 2000	A
6091995	Ingle et al.	Jul 2000	A
6093166	Knudson et al.	Jul 2000	A
6096021	Helm et al.	Aug 2000	A
6099526	Whayne et al.	Aug 2000	A
6102908	Tu et al.	Aug 2000	A
6106477	Miesel et al.	Aug 2000	A
6110187	Donlon et al.	Aug 2000	A
6114311	Parmacek et al.	Sep 2000	A
6117101	Diederich et al.	Sep 2000	A
6117128	Gregory	Sep 2000	A
6120476	Fung et al.	Sep 2000	A
6120516	Selmon et al.	Sep 2000	A
6121775	Pearlman	Sep 2000	A
6123679	Lafaut et al.	Sep 2000	A
6123682	Knudson et al.	Sep 2000	A
6123702	Swanson et al.	Sep 2000	A
6123703	Tu et al.	Sep 2000	A
6123718	Tu et al.	Sep 2000	A
6129725	Tu et al.	Oct 2000	A
6135997	Laufer et al.	Oct 2000	A
6139546	Koenig et al.	Oct 2000	A
6142991	Schatzberger	Nov 2000	A
6142993	Whayne et al.	Nov 2000	A
6149647	Tu et al.	Nov 2000	A
6152899	Farley et al.	Nov 2000	A
6152912	Jansen et al.	Nov 2000	A
6156046	Passafaro et al.	Dec 2000	A
6158250	Tibbals et al.	Dec 2000	A
6159187	Park et al.	Dec 2000	A
6159225	Makower	Dec 2000	A
6161048	Sluijter et al.	Dec 2000	A
6162184	Swanson et al.	Dec 2000	A
6165163	Chien et al.	Dec 2000	A
6165172	Farley et al.	Dec 2000	A
6165187	Reger	Dec 2000	A
6168594	Lafontaine et al.	Jan 2001	B1
6171321	Gifford, III et al.	Jan 2001	B1
6179832	Jones et al.	Jan 2001	B1
6179835	Panescu et al.	Jan 2001	B1
6179859	Bates et al.	Jan 2001	B1
6183468	Swanson et al.	Feb 2001	B1
6183486	Snow et al.	Feb 2001	B1
6190379	Heuser et al.	Feb 2001	B1
6191862	Swanson et al.	Feb 2001	B1
6197021	Panescu et al.	Mar 2001	B1
6200266	Shokrollahi et al.	Mar 2001	B1
6203537	Adrian	Mar 2001	B1
6203561	Ramee et al.	Mar 2001	B1
6210406	Webster	Apr 2001	B1
6211247	Goodman	Apr 2001	B1
6216704	Ingle et al.	Apr 2001	B1
6217576	Tu et al.	Apr 2001	B1
6219577	Brown, III et al.	Apr 2001	B1
6228076	Winston et al.	May 2001	B1
6228109	Tu et al.	May 2001	B1
6231516	Keilman et al.	May 2001	B1
6231587	Makower	May 2001	B1
6235044	Root et al.	May 2001	B1
6236883	Ciaccio et al.	May 2001	B1
6237605	Vaska et al.	May 2001	B1
6238389	Paddock et al.	May 2001	B1
6238392	Long	May 2001	B1
6241666	Pomeranz et al.	Jun 2001	B1
6241753	Knowlton	Jun 2001	B1
6245020	Moore et al.	Jun 2001	B1
6245045	Stratienko	Jun 2001	B1
6248126	Lesser et al.	Jun 2001	B1
6251128	Knopp et al.	Jun 2001	B1
6258087	Edwards et al.	Jul 2001	B1
6273886	Edwards et al.	Aug 2001	B1
6280466	Kugler et al.	Aug 2001	B1
6283935	Laufer et al.	Sep 2001	B1
6283959	Lalonde et al.	Sep 2001	B1
6284743	Parmacek et al.	Sep 2001	B1
6287323	Hammerslag	Sep 2001	B1
6290696	Lafontaine	Sep 2001	B1
6292695	Webster, Jr. et al.	Sep 2001	B1
6293942	Goble et al.	Sep 2001	B1
6293943	Panescu et al.	Sep 2001	B1
6296619	Brisken et al.	Oct 2001	B1
6298256	Meyer	Oct 2001	B1
6299379	Lewis	Oct 2001	B1
6299623	Wulfman	Oct 2001	B1
6309379	Willard et al.	Oct 2001	B1
6309399	Barbut et al.	Oct 2001	B1
6311090	Knowlton	Oct 2001	B1
6317615	KenKnight et al.	Nov 2001	B1
6319242	Patterson et al.	Nov 2001	B1
6319251	Tu et al.	Nov 2001	B1
6322559	Daulton et al.	Nov 2001	B1
6325797	Stewart et al.	Dec 2001	B1
6325799	Goble	Dec 2001	B1
6328699	Eigler et al.	Dec 2001	B1
6346074	Roth	Feb 2002	B1
6346104	Daly et al.	Feb 2002	B2
6350248	Knudson et al.	Feb 2002	B1
6350276	Knowlton	Feb 2002	B1
6353751	Swanson et al.	Mar 2002	B1
6355029	Joye et al.	Mar 2002	B1
6357447	Swanson et al.	Mar 2002	B1
6361519	Knudson et al.	Mar 2002	B1
6364840	Crowley	Apr 2002	B1
6371965	Gifford, III et al.	Apr 2002	B2
6375668	Gifford et al.	Apr 2002	B1
6377854	Knowlton	Apr 2002	B1
6377855	Knowlton	Apr 2002	B1
6379352	Reynolds et al.	Apr 2002	B1
6379373	Sawhney et al.	Apr 2002	B1
6381497	Knowlton	Apr 2002	B1
6381498	Knowlton	Apr 2002	B1
6383151	Diederich et al.	May 2002	B1
6387105	Gifford, III et al.	May 2002	B1
6387380	Knowlton	May 2002	B1
6389311	Whayne et al.	May 2002	B1
6389314	Feiring	May 2002	B2
6391024	Sun et al.	May 2002	B1
6394096	Constantz	May 2002	B1
6394956	Chandrasekaran et al.	May 2002	B1
6398780	Farley et al.	Jun 2002	B1
6398782	Pecor et al.	Jun 2002	B1
6398792	O'Connor	Jun 2002	B1
6401720	Stevens et al.	Jun 2002	B1
6402719	Ponzi et al.	Jun 2002	B1
6405090	Knowlton	Jun 2002	B1
6409723	Edwards	Jun 2002	B1
6413255	Stern	Jul 2002	B1
6421559	Pearlman	Jul 2002	B1
6423057	He et al.	Jul 2002	B1
6425867	Vaezy et al.	Jul 2002	B1
6425912	Knowlton	Jul 2002	B1
6427089	Knowlton	Jul 2002	B1
6427118	Suzuki	Jul 2002	B1
6428534	Joye et al.	Aug 2002	B1
6428536	Panescu et al.	Aug 2002	B2
6430446	Knowlton	Aug 2002	B1
6432102	Joye et al.	Aug 2002	B2
6436056	Wang et al.	Aug 2002	B1
6438424	Knowlton	Aug 2002	B1
6440125	Rentrop	Aug 2002	B1
6442413	Silver	Aug 2002	B1
6443965	Gifford, III et al.	Sep 2002	B1
6445939	Swanson et al.	Sep 2002	B1
6447505	McGovern et al.	Sep 2002	B2
6447509	Bonnet et al.	Sep 2002	B1
6451034	Gifford, III et al.	Sep 2002	B1
6451044	Naghavi et al.	Sep 2002	B1
6453202	Knowlton	Sep 2002	B1
6454737	Nita et al.	Sep 2002	B1
6454757	Nita et al.	Sep 2002	B1
6454775	Demarais et al.	Sep 2002	B1
6458098	Kanesaka	Oct 2002	B1
6458121	Rosenstock et al.	Oct 2002	B1
6461378	Knowlton	Oct 2002	B1
6468276	McKay	Oct 2002	B1
6468297	Williams et al.	Oct 2002	B1
6470216	Knowlton	Oct 2002	B1
6470219	Edwards et al.	Oct 2002	B1
6471696	Berube et al.	Oct 2002	B1
6475213	Whayne et al.	Nov 2002	B1
6475215	Tanrisever	Nov 2002	B1
6475238	Fedida et al.	Nov 2002	B1
6477426	Fenn et al.	Nov 2002	B1
6480745	Nelson et al.	Nov 2002	B2
6481704	Koster et al.	Nov 2002	B1
6482202	Goble et al.	Nov 2002	B1
6484052	Visuri et al.	Nov 2002	B1
6485489	Teirstein et al.	Nov 2002	B2
6488679	Swanson et al.	Dec 2002	B1
6489307	Phillips et al.	Dec 2002	B1
6491705	Gifford, III et al.	Dec 2002	B2
6494891	Cornish et al.	Dec 2002	B1
6497711	Plaia et al.	Dec 2002	B1
6500172	Panescu et al.	Dec 2002	B1
6500174	Maguire et al.	Dec 2002	B1
6508765	Suorsa et al.	Jan 2003	B2
6508804	Sarge et al.	Jan 2003	B2
6508815	Strul et al.	Jan 2003	B1
6511478	Burnside et al.	Jan 2003	B1
6511496	Huter et al.	Jan 2003	B1
6511500	Rahme	Jan 2003	B1
6514236	Stratienko	Feb 2003	B1
6514245	Williams et al.	Feb 2003	B1
6514248	Eggers et al.	Feb 2003	B1
6517534	McGovern et al.	Feb 2003	B1
6517572	Kugler et al.	Feb 2003	B2
6522913	Swanson et al.	Feb 2003	B2
6522926	Kieval et al.	Feb 2003	B1
6524274	Rosenthal et al.	Feb 2003	B1
6524299	Tran et al.	Feb 2003	B1
6527765	Kelman et al.	Mar 2003	B2
6527769	Langberg et al.	Mar 2003	B2
6540761	Houser	Apr 2003	B2
6542781	Koblish et al.	Apr 2003	B1
6544780	Wang	Apr 2003	B1
6546272	MacKinnon et al.	Apr 2003	B1
6547788	Maguire et al.	Apr 2003	B1
6549800	Atalar et al.	Apr 2003	B1
6552796	Magnin et al.	Apr 2003	B2
6554780	Sampson et al.	Apr 2003	B1
6558381	Ingle et al.	May 2003	B2
6558382	Jahns et al.	May 2003	B2
6564096	Mest	May 2003	B2
6565582	Gifford, III et al.	May 2003	B2
6569109	Sakurai et al.	May 2003	B2
6569177	Dillard et al.	May 2003	B1
6570659	Schmitt	May 2003	B2
6572551	Smith et al.	Jun 2003	B1
6572612	Stewart et al.	Jun 2003	B2
6577902	Laufer et al.	Jun 2003	B1
6579308	Jansen et al.	Jun 2003	B1
6579311	Makower	Jun 2003	B1
6582423	Thapliyal et al.	Jun 2003	B1
6589238	Edwards et al.	Jul 2003	B2
6592526	Lenker	Jul 2003	B1
6592567	Levin et al.	Jul 2003	B1
6595959	Stratienko	Jul 2003	B1
6600956	Maschino et al.	Jul 2003	B2
6602242	Fung et al.	Aug 2003	B1
6602246	Joye et al.	Aug 2003	B1
6605061	Vantassel et al.	Aug 2003	B2
6605084	Acker et al.	Aug 2003	B2
6623452	Chien et al.	Sep 2003	B2
6623453	Guibert et al.	Sep 2003	B1
6632193	Davison et al.	Oct 2003	B1
6632196	Houser	Oct 2003	B1
6645223	Boyle et al.	Nov 2003	B2
6648854	Patterson et al.	Nov 2003	B1
6648878	Lafontaine	Nov 2003	B2
6648879	Joye et al.	Nov 2003	B2
6651672	Roth	Nov 2003	B2
6652513	Panescu et al.	Nov 2003	B2
6652515	Maguire et al.	Nov 2003	B1
6656136	Weng et al.	Dec 2003	B1
6658279	Swanson et al.	Dec 2003	B2
6659981	Stewart et al.	Dec 2003	B2
6666858	Lafontaine	Dec 2003	B2
6666863	Wentzel et al.	Dec 2003	B2
6669655	Acker et al.	Dec 2003	B1
6669692	Nelson et al.	Dec 2003	B1
6673040	Samson et al.	Jan 2004	B1
6673064	Rentrop	Jan 2004	B1
6673066	Werneth	Jan 2004	B2
6673090	Root et al.	Jan 2004	B2
6673101	Fitzgerald et al.	Jan 2004	B1
6673290	Whayne et al.	Jan 2004	B1
6676678	Gifford, III et al.	Jan 2004	B2
6679268	Stevens et al.	Jan 2004	B2
6681773	Murphy et al.	Jan 2004	B2
6682541	Gifford, III et al.	Jan 2004	B1
6684098	Oshio et al.	Jan 2004	B2
6685732	Kramer	Feb 2004	B2
6685733	Dae et al.	Feb 2004	B1
6689086	Nita et al.	Feb 2004	B1
6689148	Sawhney et al.	Feb 2004	B2
6690181	Dowdeswell et al.	Feb 2004	B1
6692490	Edwards	Feb 2004	B1
6695830	Vigil et al.	Feb 2004	B2
6695857	Gifford, III et al.	Feb 2004	B2
6699241	Rappaport et al.	Mar 2004	B2
6699257	Gifford, III et al.	Mar 2004	B2
6702748	Nita et al.	Mar 2004	B1
6702811	Stewart et al.	Mar 2004	B2
6706010	Miki et al.	Mar 2004	B1
6706011	Murphy-Chutorian et al.	Mar 2004	B1
6706037	Zvuloni et al.	Mar 2004	B2
6709431	Lafontaine	Mar 2004	B2
6711429	Gilboa et al.	Mar 2004	B1
6712815	Sampson et al.	Mar 2004	B2
6714822	King et al.	Mar 2004	B2
6716184	Vaezy et al.	Apr 2004	B2
6720350	Kunz et al.	Apr 2004	B2
6723043	Kleeman et al.	Apr 2004	B2
6723064	Babaev	Apr 2004	B2
6736811	Panescu et al.	May 2004	B2
6743184	Sampson et al.	Jun 2004	B2
6746401	Panescu	Jun 2004	B2
6746464	Makower	Jun 2004	B1
6746474	Saadat	Jun 2004	B2
6748953	Sherry et al.	Jun 2004	B2
6749607	Edwards et al.	Jun 2004	B2
6752805	Maguire et al.	Jun 2004	B2
6760616	Hoey et al.	Jul 2004	B2
6763261	Casscells, III et al.	Jul 2004	B2
6764501	Ganz	Jul 2004	B2
6769433	Zikorus et al.	Aug 2004	B2
6770070	Balbierz	Aug 2004	B1
6771996	Bowe et al.	Aug 2004	B2
6773433	Stewart et al.	Aug 2004	B2
6786900	Joye et al.	Sep 2004	B2
6786901	Joye et al.	Sep 2004	B2
6786904	Döscher et al.	Sep 2004	B2
6788977	Fenn et al.	Sep 2004	B2
6790206	Panescu	Sep 2004	B2
6790222	Kugler et al.	Sep 2004	B2
6796981	Wham et al.	Sep 2004	B2
6797933	Mendis et al.	Sep 2004	B1
6797960	Spartiotis et al.	Sep 2004	B1
6800075	Mische et al.	Oct 2004	B2
6802857	Walsh et al.	Oct 2004	B1
6807444	Tu et al.	Oct 2004	B2
6811550	Holland et al.	Nov 2004	B2
6813520	Truckai et al.	Nov 2004	B2
6814730	Li	Nov 2004	B2
6814733	Schwartz et al.	Nov 2004	B2
6823205	Jara	Nov 2004	B1
6824516	Batten et al.	Nov 2004	B2
6827726	Parodi	Dec 2004	B2
6827926	Robinson et al.	Dec 2004	B2
6829497	Mogul	Dec 2004	B2
6830568	Kesten et al.	Dec 2004	B1
6837886	Collins et al.	Jan 2005	B2
6837888	Ciarrocca et al.	Jan 2005	B2
6845267	Harrison	Jan 2005	B2
6847848	Sterzer	Jan 2005	B2
6849073	Hoey et al.	Feb 2005	B2
6849075	Bertolero et al.	Feb 2005	B2
6853425	Kim et al.	Feb 2005	B2
6855123	Nita	Feb 2005	B2
6855143	Davison	Feb 2005	B2
6869431	Maguire et al.	Mar 2005	B2
6872183	Sampson et al.	Mar 2005	B2
6884260	Kugler et al.	Apr 2005	B2
6889694	Hooven	May 2005	B2
6893436	Woodard et al.	May 2005	B2
6895077	Karellas et al.	May 2005	B2
6895265	Silver	May 2005	B2
6898454	Atalar et al.	May 2005	B2
6899711	Stewart et al.	May 2005	B2
6899718	Gifford, III et al.	May 2005	B2
6905494	Yon et al.	Jun 2005	B2
6908462	Joye et al.	Jun 2005	B2
6909009	Koridze	Jun 2005	B2
6911026	Hall et al.	Jun 2005	B1
6915806	Pacek et al.	Jul 2005	B2
6923805	LaFontaine et al.	Aug 2005	B1
6926246	Ginggen	Aug 2005	B2
6926713	Rioux et al.	Aug 2005	B2
6926716	Baker et al.	Aug 2005	B2
6929009	Makower et al.	Aug 2005	B2
6929632	Nita et al.	Aug 2005	B2
6929639	Lafontaine	Aug 2005	B2
6932776	Carr	Aug 2005	B2
6936047	Nasab et al.	Aug 2005	B2
6942620	Nita et al.	Sep 2005	B2
6942657	Sinofsky et al.	Sep 2005	B2
6942677	Nita et al.	Sep 2005	B2
6942692	Landau et al.	Sep 2005	B2
6949097	Stewart et al.	Sep 2005	B2
6949121	Laguna	Sep 2005	B1
6952615	Satake	Oct 2005	B2
6953425	Brister	Oct 2005	B2
6955174	Joye et al.	Oct 2005	B2
6955175	Stevens et al.	Oct 2005	B2
6958075	Mon et al.	Oct 2005	B2
6959711	Murphy et al.	Nov 2005	B2
6960207	Vanney et al.	Nov 2005	B2
6962584	Stone et al.	Nov 2005	B1
6962587	Johnson et al.	Nov 2005	B2
6964660	Maguire et al.	Nov 2005	B2
6966908	Maguire et al.	Nov 2005	B2
6972015	Joye et al.	Dec 2005	B2
6972024	Kilpatrick et al.	Dec 2005	B1
6974456	Edwards et al.	Dec 2005	B2
6978174	Gelfand et al.	Dec 2005	B2
6979329	Burnside et al.	Dec 2005	B2
6979420	Weber	Dec 2005	B2
6984238	Gifford, III et al.	Jan 2006	B2
6985774	Kieval et al.	Jan 2006	B2
6986739	Warren et al.	Jan 2006	B2
6989009	Lafontaine	Jan 2006	B2
6989010	Francischelli et al.	Jan 2006	B2
6991617	Hektner et al.	Jan 2006	B2
7001378	Yon et al.	Feb 2006	B2
7006858	Silver et al.	Feb 2006	B2
7008667	Chudzik et al.	Mar 2006	B2
7011508	Lum	Mar 2006	B2
7022105	Edwards	Apr 2006	B1
7022120	Lafontaine	Apr 2006	B2
7025767	Schaefer et al.	Apr 2006	B2
7033322	Silver	Apr 2006	B2
7033372	Cahalan	Apr 2006	B1
7041098	Farley et al.	May 2006	B2
7050848	Hoey et al.	May 2006	B2
7063670	Sampson et al.	Jun 2006	B2
7063679	Maguire et al.	Jun 2006	B2
7063719	Jansen et al.	Jun 2006	B2
7066895	Podany	Jun 2006	B2
7066900	Botto et al.	Jun 2006	B2
7066904	Rosenthal et al.	Jun 2006	B2
7072720	Puskas	Jul 2006	B2
7074217	Strul et al.	Jul 2006	B2
7081112	Joye et al.	Jul 2006	B2
7081114	Rashidi	Jul 2006	B2
7083614	Fjield et al.	Aug 2006	B2
7084276	Vu et al.	Aug 2006	B2
7087026	Callister et al.	Aug 2006	B2
7087051	Bourne et al.	Aug 2006	B2
7087052	Sampson et al.	Aug 2006	B2
7087053	Vanney	Aug 2006	B2
7089065	Westlund et al.	Aug 2006	B2
7097641	Arless et al.	Aug 2006	B1
7100614	Stevens et al.	Sep 2006	B2
7101368	Lafontaine	Sep 2006	B2
7104983	Grasso, III et al.	Sep 2006	B2
7104987	Biggs et al.	Sep 2006	B2
7108715	Lawrence-Brown et al.	Sep 2006	B2
7112196	Brosch et al.	Sep 2006	B2
7112198	Satake	Sep 2006	B2
7112211	Gifford, III et al.	Sep 2006	B2
7122019	Kesten et al.	Oct 2006	B1
7122033	Wood	Oct 2006	B2
7134438	Makower et al.	Nov 2006	B2
7137963	Nita et al.	Nov 2006	B2
7137980	Buysse et al.	Nov 2006	B2
7153315	Miller	Dec 2006	B2
7155271	Halperin et al.	Dec 2006	B2
7157491	Mewshaw et al.	Jan 2007	B2
7157492	Mewshaw et al.	Jan 2007	B2
7158832	Kieval et al.	Jan 2007	B2
7160296	Pearson et al.	Jan 2007	B2
7162303	Levin et al.	Jan 2007	B2
7165551	Edwards et al.	Jan 2007	B2
7169144	Hoey et al.	Jan 2007	B2
7172589	Lafontaine	Feb 2007	B2
7172610	Heitzmann et al.	Feb 2007	B2
7181261	Silver et al.	Feb 2007	B2
7184811	Phan et al.	Feb 2007	B2
7184827	Edwards	Feb 2007	B1
7189227	Lafontaine	Mar 2007	B2
7192427	Chapelon et al.	Mar 2007	B2
7192586	Bander	Mar 2007	B2
7197354	Sobe	Mar 2007	B2
7198632	Lim et al.	Apr 2007	B2
7200445	Dalbec et al.	Apr 2007	B1
7201749	Govari et al.	Apr 2007	B2
7203537	Mower	Apr 2007	B2
7214234	Rapacki et al.	May 2007	B2
7220233	Nita et al.	May 2007	B2
7220239	Wilson et al.	May 2007	B2
7220257	Lafontaine	May 2007	B1
7220270	Sawhney et al.	May 2007	B2
7232458	Saadat	Jun 2007	B2
7232459	Greenberg et al.	Jun 2007	B2
7238184	Megerman et al.	Jul 2007	B2
7241273	Maguire et al.	Jul 2007	B2
7241736	Hunter et al.	Jul 2007	B2
7247141	Makin et al.	Jul 2007	B2
7250041	Chiu et al.	Jul 2007	B2
7250440	Mewshaw et al.	Jul 2007	B2
7252664	Nasab et al.	Aug 2007	B2
7252679	Fischell et al.	Aug 2007	B2
7264619	Venturelli	Sep 2007	B2
7279600	Mewshaw et al.	Oct 2007	B2
7280863	Shachar	Oct 2007	B2
7282213	Schroeder et al.	Oct 2007	B2
7285119	Stewart et al.	Oct 2007	B2
7285120	Im et al.	Oct 2007	B2
7288089	Yon et al.	Oct 2007	B2
7288096	Chin	Oct 2007	B2
7291146	Steinke et al.	Nov 2007	B2
7293562	Malecki et al.	Nov 2007	B2
7294125	Phalen et al.	Nov 2007	B2
7294126	Sampson et al.	Nov 2007	B2
7294127	Leung et al.	Nov 2007	B2
7297131	Nita	Nov 2007	B2
7297475	Koiwai et al.	Nov 2007	B2
7300433	Lane et al.	Nov 2007	B2
7301108	Egitto et al.	Nov 2007	B2
7310150	Guillermo et al.	Dec 2007	B2
7313430	Urquhart et al.	Dec 2007	B2
7314483	Landau et al.	Jan 2008	B2
7317077	Averback et al.	Jan 2008	B2
7323006	Andreas et al.	Jan 2008	B2
7326206	Paul et al.	Feb 2008	B2
7326226	Root et al.	Feb 2008	B2
7326235	Edwards	Feb 2008	B2
7326237	DePalma et al.	Feb 2008	B2
7329236	Kesten et al.	Feb 2008	B2
7335180	Nita et al.	Feb 2008	B2
7335192	Keren et al.	Feb 2008	B2
7338467	Lutter	Mar 2008	B2
7341570	Keren et al.	Mar 2008	B2
7343195	Strommer et al.	Mar 2008	B2
7347857	Anderson et al.	Mar 2008	B2
7348003	Salcedo et al.	Mar 2008	B2
7352593	Zeng et al.	Apr 2008	B2
7354927	Vu	Apr 2008	B2
7359732	Kim et al.	Apr 2008	B2
7361341	Salcedo et al.	Apr 2008	B2
7364566	Elkins et al.	Apr 2008	B2
7367970	Govari et al.	May 2008	B2
7367975	Malecki et al.	May 2008	B2
7371231	Rioux et al.	May 2008	B2
7387126	Cox et al.	Jun 2008	B2
7393338	Nita	Jul 2008	B2
7396355	Goldman et al.	Jul 2008	B2
7402151	Rosenman et al.	Jul 2008	B2
7402312	Rosen et al.	Jul 2008	B2
7404824	Webler et al.	Jul 2008	B1
7406970	Zikorus et al.	Aug 2008	B2
7407502	Strul et al.	Aug 2008	B2
7407506	Makower	Aug 2008	B2
7407671	McBride et al.	Aug 2008	B2
7408021	Averback et al.	Aug 2008	B2
7410486	Fuimaono et al.	Aug 2008	B2
7413556	Zhang et al.	Aug 2008	B2
7425212	Danek et al.	Sep 2008	B1
7426409	Casscells, III et al.	Sep 2008	B2
7435248	Taimisto et al.	Oct 2008	B2
7447453	Kim et al.	Nov 2008	B2
7449018	Kramer	Nov 2008	B2
7452538	Ni et al.	Nov 2008	B2
7473890	Grier et al.	Jan 2009	B2
7476384	Ni et al.	Jan 2009	B2
7479157	Weber et al.	Jan 2009	B2
7481803	Kesten et al.	Jan 2009	B2
7485104	Kieval	Feb 2009	B2
7486805	Krattiger	Feb 2009	B2
7487780	Hooven	Feb 2009	B2
7493154	Bonner et al.	Feb 2009	B2
7494485	Beck et al.	Feb 2009	B2
7494486	Mische et al.	Feb 2009	B2
7494488	Weber	Feb 2009	B2
7494661	Sanders	Feb 2009	B2
7495439	Wiggins	Feb 2009	B2
7497858	Chapelon et al.	Mar 2009	B2
7499745	Littrup et al.	Mar 2009	B2
7500985	Saadat	Mar 2009	B2
7505812	Eggers et al.	Mar 2009	B1
7505816	Schmeling et al.	Mar 2009	B2
7507233	Littrup et al.	Mar 2009	B2
7507235	Keogh et al.	Mar 2009	B2
7511494	Wedeen	Mar 2009	B2
7512445	Truckai et al.	Mar 2009	B2
7527643	Case et al.	May 2009	B2
7529589	Williams et al.	May 2009	B2
7540852	Nita et al.	Jun 2009	B2
7540870	Babaev	Jun 2009	B2
RE40863	Tay et al.	Jul 2009	E
7556624	Laufer et al.	Jul 2009	B2
7558625	Levin et al.	Jul 2009	B2
7563247	Maguire et al.	Jul 2009	B2
7566319	McAuley et al.	Jul 2009	B2
7569052	Phan et al.	Aug 2009	B2
7582111	Krolik et al.	Sep 2009	B2
7584004	Caparso et al.	Sep 2009	B2
7585835	Hill et al.	Sep 2009	B2
7591996	Hwang et al.	Sep 2009	B2
7597704	Frazier et al.	Oct 2009	B2
7598228	Hattori et al.	Oct 2009	B2
7599730	Hunter et al.	Oct 2009	B2
7603166	Casscells, III et al.	Oct 2009	B2
7604608	Nita et al.	Oct 2009	B2
7604633	Truckai et al.	Oct 2009	B2
7615015	Coleman	Nov 2009	B2
7615072	Rust et al.	Nov 2009	B2
7617005	Demarais et al.	Nov 2009	B2
7620451	Demarais et al.	Nov 2009	B2
7621902	Nita et al.	Nov 2009	B2
7621929	Nita et al.	Nov 2009	B2
7626015	Feinstein et al.	Dec 2009	B2
7626235	Kinoshita	Dec 2009	B2
7632268	Edwards et al.	Dec 2009	B2
7632845	Vu et al.	Dec 2009	B2
7635383	Gumm	Dec 2009	B2
7640046	Pastore et al.	Dec 2009	B2
7641633	Laufer et al.	Jan 2010	B2
7641679	Joye et al.	Jan 2010	B2
7646544	Batchko et al.	Jan 2010	B2
7647115	Levin et al.	Jan 2010	B2
7653438	Deem et al.	Jan 2010	B2
7655006	Sauvageau et al.	Feb 2010	B2
7662114	Seip et al.	Feb 2010	B2
7664548	Amurthur et al.	Feb 2010	B2
7670279	Gertner	Mar 2010	B2
7670335	Keidar	Mar 2010	B2
7671084	Mewshaw et al.	Mar 2010	B2
7678104	Keidar	Mar 2010	B2
7678106	Lee	Mar 2010	B2
7678108	Chrisitian et al.	Mar 2010	B2
7691080	Seward et al.	Apr 2010	B2
7699809	Urmey	Apr 2010	B2
7706882	Francischelli et al.	Apr 2010	B2
7715912	Rezai et al.	May 2010	B2
7717853	Nita	May 2010	B2
7717909	Strul et al.	May 2010	B2
7717948	Demarais et al.	May 2010	B2
7722539	Carter et al.	May 2010	B2
7725157	Dumoulin et al.	May 2010	B2
7727178	Wilson et al.	Jun 2010	B2
7736317	Stephens et al.	Jun 2010	B2
7736360	Mody et al.	Jun 2010	B2
7736362	Eberl et al.	Jun 2010	B2
7738952	Yun et al.	Jun 2010	B2
7740629	Anderson et al.	Jun 2010	B2
7741299	Feinstein et al.	Jun 2010	B2
7742795	Stone et al.	Jun 2010	B2
7744594	Yamazaki et al.	Jun 2010	B2
7753907	DiMatteo et al.	Jul 2010	B2
7756583	Demarais et al.	Jul 2010	B2
7758510	Nita et al.	Jul 2010	B2
7758520	Griffin et al.	Jul 2010	B2
7759315	Cuzzocrea et al.	Jul 2010	B2
7766833	Lee et al.	Aug 2010	B2
7766878	Tremaglio, Jr. et al.	Aug 2010	B2
7766892	Keren et al.	Aug 2010	B2
7767844	Lee et al.	Aug 2010	B2
7769427	Shachar	Aug 2010	B2
7771372	Wilson	Aug 2010	B2
7771421	Stewart et al.	Aug 2010	B2
7776967	Perry et al.	Aug 2010	B2
7777486	Hargreaves et al.	Aug 2010	B2
7780660	Bourne et al.	Aug 2010	B2
7789876	Zikorus et al.	Sep 2010	B2
7792568	Zhong et al.	Sep 2010	B2
7799021	Leung et al.	Sep 2010	B2
7803168	Gifford et al.	Sep 2010	B2
7806871	Li et al.	Oct 2010	B2
7811265	Hering et al.	Oct 2010	B2
7811281	Rentrop	Oct 2010	B1
7811313	Mon et al.	Oct 2010	B2
7816511	Kawashima et al.	Oct 2010	B2
7818053	Kassab	Oct 2010	B2
7819866	Bednarek	Oct 2010	B2
7822460	Halperin et al.	Oct 2010	B2
7828837	Khoury	Nov 2010	B2
7832407	Gertner	Nov 2010	B2
7833220	Mon et al.	Nov 2010	B2
7837676	Sinelnikov et al.	Nov 2010	B2
7837720	Mon	Nov 2010	B2
7841978	Gertner	Nov 2010	B2
7846157	Kozel	Dec 2010	B2
7846160	Payne et al.	Dec 2010	B2
7846172	Makower	Dec 2010	B2
7849860	Makower et al.	Dec 2010	B2
7850685	Kunis et al.	Dec 2010	B2
7853333	Demarais	Dec 2010	B2
7854734	Biggs et al.	Dec 2010	B2
7857756	Warren et al.	Dec 2010	B2
7862565	Eder et al.	Jan 2011	B2
7863897	Slocum, Jr. et al.	Jan 2011	B2
7869854	Shachar et al.	Jan 2011	B2
7873417	Demarais et al.	Jan 2011	B2
7887538	Bleich et al.	Feb 2011	B2
7894905	Pless et al.	Feb 2011	B2
7896873	Hiller et al.	Mar 2011	B2
7901400	Wham et al.	Mar 2011	B2
7901402	Jones et al.	Mar 2011	B2
7901420	Dunn	Mar 2011	B2
7905862	Sampson	Mar 2011	B2
7918850	Govari et al.	Apr 2011	B2
7927370	Webler et al.	Apr 2011	B2
7937143	Demarais et al.	May 2011	B2
7938830	Saadat et al.	May 2011	B2
7942874	Eder et al.	May 2011	B2
7942928	Webler et al.	May 2011	B2
7946976	Gertner	May 2011	B2
7950397	Thapliyal et al.	May 2011	B2
7955293	Nita et al.	Jun 2011	B2
7956613	Wald	Jun 2011	B2
7959627	Utley et al.	Jun 2011	B2
7962854	Vance et al.	Jun 2011	B2
7967782	Laufer et al.	Jun 2011	B2
7967808	Fitzgerald et al.	Jun 2011	B2
7972327	Eberl et al.	Jul 2011	B2
7972330	Alejandro et al.	Jul 2011	B2
7983751	Zdeblick et al.	Jul 2011	B2
8001976	Gertner	Aug 2011	B2
8007440	Magnin et al.	Aug 2011	B2
8012147	Lafontaine	Sep 2011	B2
8019435	Hastings et al.	Sep 2011	B2
8021362	Deem et al.	Sep 2011	B2
8021413	Dierking et al.	Sep 2011	B2
8025661	Arnold et al.	Sep 2011	B2
8027718	Spinner et al.	Sep 2011	B2
8031927	Karl et al.	Oct 2011	B2
8033284	Porter et al.	Oct 2011	B2
8048144	Thistle et al.	Nov 2011	B2
8052636	Moll et al.	Nov 2011	B2
8052700	Dunn	Nov 2011	B2
8062289	Babaev	Nov 2011	B2
8075580	Makower	Dec 2011	B2
8080006	Lafontaine et al.	Dec 2011	B2
8088127	Mayse et al.	Jan 2012	B2
8116883	Williams et al.	Feb 2012	B2
8119183	O'Donoghue et al.	Feb 2012	B2
8120518	Jang et al.	Feb 2012	B2
8123741	Marrouche et al.	Feb 2012	B2
8128617	Bencini et al.	Mar 2012	B2
8131371	Demarals et al.	Mar 2012	B2
8131372	Levin et al.	Mar 2012	B2
8131382	Asada	Mar 2012	B2
8137274	Weng et al.	Mar 2012	B2
8140170	Rezai et al.	Mar 2012	B2
8143316	Ueno	Mar 2012	B2
8145316	Deem et al.	Mar 2012	B2
8145317	Demarais et al.	Mar 2012	B2
8150518	Levin et al.	Apr 2012	B2
8150519	Demarais et al.	Apr 2012	B2
8150520	Demarais et al.	Apr 2012	B2
8152830	Gumm	Apr 2012	B2
8162933	Francischelli et al.	Apr 2012	B2
8175711	Demarais et al.	May 2012	B2
8187261	Watson	May 2012	B2
8190238	Moll et al.	May 2012	B2
8192053	Owen et al.	Jun 2012	B2
8198611	LaFontaine et al.	Jun 2012	B2
8214056	Hoffer et al.	Jul 2012	B2
8221407	Phan et al.	Jul 2012	B2
8226637	Satake	Jul 2012	B2
8231617	Satake	Jul 2012	B2
8241217	Chiang et al.	Aug 2012	B2
8257724	Cromack et al.	Sep 2012	B2
8257725	Cromack et al.	Sep 2012	B2
8260397	Ruff et al.	Sep 2012	B2
8263104	Ho et al.	Sep 2012	B2
8273023	Razavi	Sep 2012	B2
8277379	Lau et al.	Oct 2012	B2
8287524	Siegel	Oct 2012	B2
8287532	Carroll et al.	Oct 2012	B2
8292881	Brannan et al.	Oct 2012	B2
8293703	Averback et al.	Oct 2012	B2
8295902	Salahieh et al.	Oct 2012	B2
8295912	Gertner	Oct 2012	B2
8308722	Ormsby et al.	Nov 2012	B2
8317776	Ferren et al.	Nov 2012	B2
8317810	Stangenes et al.	Nov 2012	B2
8329179	Ni et al.	Dec 2012	B2
8336705	Okahisa	Dec 2012	B2
8343031	Gertner	Jan 2013	B2
8343145	Brannan	Jan 2013	B2
8347891	Demarais et al.	Jan 2013	B2
8353945	Andreas et al.	Jan 2013	B2
8364237	Stone et al.	Jan 2013	B2
8366615	Razavi	Feb 2013	B2
8382697	Brenneman et al.	Feb 2013	B2
8388680	Starksen et al.	Mar 2013	B2
8396548	Perry et al.	Mar 2013	B2
8398629	Thistle	Mar 2013	B2
8401667	Gustus et al.	Mar 2013	B2
8403881	Ferren et al.	Mar 2013	B2
8406877	Smith et al.	Mar 2013	B2
8409172	Moll et al.	Apr 2013	B2
8409193	Young et al.	Apr 2013	B2
8409195	Young	Apr 2013	B2
8418362	Zerfas et al.	Apr 2013	B2
8452988	Wang	May 2013	B2
8454594	Demarais et al.	Jun 2013	B2
8460358	Andreas et al.	Jun 2013	B2
8465452	Kassab	Jun 2013	B2
8469919	Ingle et al.	Jun 2013	B2
8473067	Hastings et al.	Jun 2013	B2
8480663	Ingle et al.	Jul 2013	B2
8485992	Griffin et al.	Jul 2013	B2
8486060	Kotmel et al.	Jul 2013	B2
8486063	Werneth et al.	Jul 2013	B2
8488591	Miali et al.	Jul 2013	B2
20010007070	Stewart et al.	Jul 2001	A1
20010039419	Francischelli et al.	Nov 2001	A1
20010051774	Littrup et al.	Dec 2001	A1
20020022864	Mahvi et al.	Feb 2002	A1
20020042639	Murphy-Chutorian et al.	Apr 2002	A1
20020045811	Kittrell et al.	Apr 2002	A1
20020045890	Celliers et al.	Apr 2002	A1
20020062123	McClurken et al.	May 2002	A1
20020062146	Makower et al.	May 2002	A1
20020065542	Lax et al.	May 2002	A1
20020072686	Hoey et al.	Jun 2002	A1
20020077592	Barry	Jun 2002	A1
20020082552	Ding et al.	Jun 2002	A1
20020087151	Mody et al.	Jul 2002	A1
20020087156	Maguire et al.	Jul 2002	A1
20020091381	Edwards	Jul 2002	A1
20020095197	Lardo et al.	Jul 2002	A1
20020107511	Collins et al.	Aug 2002	A1
20020107536	Hussein	Aug 2002	A1
20020143324	Edwards	Oct 2002	A1
20020147480	Mamayek	Oct 2002	A1
20020169444	Mest et al.	Nov 2002	A1
20020198520	Coen et al.	Dec 2002	A1
20030004510	Wham et al.	Jan 2003	A1
20030028114	Casscells, III et al.	Feb 2003	A1
20030050635	Truckai et al.	Mar 2003	A1
20030060857	Perrson et al.	Mar 2003	A1
20030060858	Kieval et al.	Mar 2003	A1
20030065317	Rudie et al.	Apr 2003	A1
20030069619	Fenn et al.	Apr 2003	A1
20030088189	Tu et al.	May 2003	A1
20030092995	Thompson	May 2003	A1
20030114791	Rosenthal et al.	Jun 2003	A1
20030139689	Shturman et al.	Jul 2003	A1
20030195501	Sherman et al.	Oct 2003	A1
20030199747	Michlitsch et al.	Oct 2003	A1
20030212394	Pearson et al.	Nov 2003	A1
20030220639	Chapelon et al.	Nov 2003	A1
20030229340	Sherry et al.	Dec 2003	A1
20030229384	Mon	Dec 2003	A1
20040000633	Arnold et al.	Jan 2004	A1
20040006359	Laguna	Jan 2004	A1
20040010118	Zerhusen et al.	Jan 2004	A1
20040019348	Stevens et al.	Jan 2004	A1
20040024371	Plicchi et al.	Feb 2004	A1
20040043030	Griffiths et al.	Mar 2004	A1
20040062852	Schroeder et al.	Apr 2004	A1
20040064090	Keren et al.	Apr 2004	A1
20040064093	Hektner et al.	Apr 2004	A1
20040073206	Foley et al.	Apr 2004	A1
20040082946	Malis et al.	Apr 2004	A1
20040088002	Boyle et al.	May 2004	A1
20040093055	Bartorelli et al.	May 2004	A1
20040106871	Hunyor et al.	Jun 2004	A1
20040111016	Casscells, III et al.	Jun 2004	A1
20040117032	Roth	Jun 2004	A1
20040122421	Wood	Jun 2004	A1
20040147915	Hasebe	Jul 2004	A1
20040162555	Farley et al.	Aug 2004	A1
20040167506	Chen	Aug 2004	A1
20040181165	Hoey et al.	Sep 2004	A1
20040186356	O'Malley et al.	Sep 2004	A1
20040186468	Edwards	Sep 2004	A1
20040187875	He et al.	Sep 2004	A1
20040193211	Voegele et al.	Sep 2004	A1
20040220556	Cooper et al.	Nov 2004	A1
20040243022	Carney et al.	Dec 2004	A1
20040243199	Mon et al.	Dec 2004	A1
20040253304	Gross et al.	Dec 2004	A1
20040267250	Yon et al.	Dec 2004	A1
20050010095	Stewart et al.	Jan 2005	A1
20050010208	Winston et al.	Jan 2005	A1
20050015125	Mioduski et al.	Jan 2005	A1
20050033136	Govari et al.	Feb 2005	A1
20050080374	Esch et al.	Apr 2005	A1
20050090820	Cornelius et al.	Apr 2005	A1
20050096647	Steinke et al.	May 2005	A1
20050129616	Salcedo et al.	Jun 2005	A1
20050137180	Robinson et al.	Jun 2005	A1
20050143817	Hunter et al.	Jun 2005	A1
20050148842	Wang et al.	Jul 2005	A1
20050149069	Bertolero et al.	Jul 2005	A1
20050149080	Hunter et al.	Jul 2005	A1
20050149158	Hunter et al.	Jul 2005	A1
20050149173	Hunter et al.	Jul 2005	A1
20050149175	Hunter et al.	Jul 2005	A1
20050154277	Tang et al.	Jul 2005	A1
20050154445	Hunter et al.	Jul 2005	A1
20050154453	Hunter et al.	Jul 2005	A1
20050154454	Hunter et al.	Jul 2005	A1
20050165389	Swain et al.	Jul 2005	A1
20050165391	Maguire et al.	Jul 2005	A1
20050165467	Hunter et al.	Jul 2005	A1
20050165488	Hunter et al.	Jul 2005	A1
20050175661	Hunter et al.	Aug 2005	A1
20050175662	Hunter et al.	Aug 2005	A1
20050175663	Hunter et al.	Aug 2005	A1
20050177103	Hunter et al.	Aug 2005	A1
20050177225	Hunter et al.	Aug 2005	A1
20050181004	Hunter et al.	Aug 2005	A1
20050181008	Hunter et al.	Aug 2005	A1
20050181011	Hunter et al.	Aug 2005	A1
20050181977	Hunter et al.	Aug 2005	A1
20050182479	Bonsignore et al.	Aug 2005	A1
20050183728	Hunter et al.	Aug 2005	A1
20050186242	Hunter et al.	Aug 2005	A1
20050186243	Hunter et al.	Aug 2005	A1
20050191331	Hunter et al.	Sep 2005	A1
20050203410	Jenkins	Sep 2005	A1
20050203434	Kassab	Sep 2005	A1
20050203498	Mon et al.	Sep 2005	A1
20050209587	Joye et al.	Sep 2005	A1
20050214205	Salcedo et al.	Sep 2005	A1
20050214207	Salcedo et al.	Sep 2005	A1
20050214208	Salcedo et al.	Sep 2005	A1
20050214209	Salcedo et al.	Sep 2005	A1
20050214210	Salcedo et al.	Sep 2005	A1
20050214268	Cavanagh et al.	Sep 2005	A1
20050228286	Messerly et al.	Oct 2005	A1
20050228415	Gertner	Oct 2005	A1
20050228460	Levin et al.	Oct 2005	A1
20050232921	Rosen et al.	Oct 2005	A1
20050234312	Suzuki et al.	Oct 2005	A1
20050245862	Seward	Nov 2005	A1
20050251116	Steinke et al.	Nov 2005	A1
20050252553	Ginggen	Nov 2005	A1
20050256398	Hastings et al.	Nov 2005	A1
20050267556	Shuros et al.	Dec 2005	A1
20050283195	Pastore et al.	Dec 2005	A1
20060004323	Chang et al.	Jan 2006	A1
20060018949	Ammon et al.	Jan 2006	A1
20060024564	Manclaw et al.	Feb 2006	A1
20060025765	Landman et al.	Feb 2006	A1
20060062786	Salcedo et al.	Mar 2006	A1
20060079882	Swoyer et al.	Apr 2006	A1
20060083194	Dhrimaj et al.	Apr 2006	A1
20060085054	Zikorus et al.	Apr 2006	A1
20060089637	Werneth et al.	Apr 2006	A1
20060089638	Carmel et al.	Apr 2006	A1
20060095096	DeBenedictis et al.	May 2006	A1
20060106375	Werneth et al.	May 2006	A1
20060142790	Gertner	Jun 2006	A1
20060147492	Hunter et al.	Jul 2006	A1
20060149166	Zvuloni	Jul 2006	A1
20060167106	Zhang et al.	Jul 2006	A1
20060167498	DiLorenzo	Jul 2006	A1
20060171895	Bucay-Couto	Aug 2006	A1
20060184060	Belalcazar et al.	Aug 2006	A1
20060184221	Stewart et al.	Aug 2006	A1
20060195139	Gertner	Aug 2006	A1
20060206150	Demarais et al.	Sep 2006	A1
20060224153	Fischell et al.	Oct 2006	A1
20060235286	Stone et al.	Oct 2006	A1
20060239921	Mangat et al.	Oct 2006	A1
20060240070	Cromack et al.	Oct 2006	A1
20060246143	Ege	Nov 2006	A1
20060247266	Yamada et al.	Nov 2006	A1
20060247760	Ganesan et al.	Nov 2006	A1
20060263393	Demopulos et al.	Nov 2006	A1
20060269555	Salcedo et al.	Nov 2006	A1
20060271111	Demarais et al.	Nov 2006	A1
20060280858	Kokish	Dec 2006	A1
20060287644	Inganas et al.	Dec 2006	A1
20060293649	Lorang et al.	Dec 2006	A1
20070016184	Cropper et al.	Jan 2007	A1
20070016274	Boveja et al.	Jan 2007	A1
20070027390	Maschke et al.	Feb 2007	A1
20070043077	Mewshaw et al.	Feb 2007	A1
20070043409	Brian et al.	Feb 2007	A1
20070049924	Rahn	Mar 2007	A1
20070066972	Ormsby et al.	Mar 2007	A1
20070073151	Lee	Mar 2007	A1
20070078498	Rezai et al.	Apr 2007	A1
20070093710	Maschke	Apr 2007	A1
20070100405	Thompson et al.	May 2007	A1
20070106247	Burnett et al.	May 2007	A1
20070112327	Yun et al.	May 2007	A1
20070118107	Francischelli et al.	May 2007	A1
20070129760	Demarais et al.	Jun 2007	A1
20070129761	Demarais et al.	Jun 2007	A1
20070135875	Demarais et al.	Jun 2007	A1
20070149963	Matsukuma et al.	Jun 2007	A1
20070162109	Davila et al.	Jul 2007	A1
20070173805	Weinberg et al.	Jul 2007	A1
20070173899	Levin et al.	Jul 2007	A1
20070179496	Swoyer et al.	Aug 2007	A1
20070197891	Shachar et al.	Aug 2007	A1
20070203480	Mody et al.	Aug 2007	A1
20070207186	Scanlon et al.	Sep 2007	A1
20070208134	Hunter et al.	Sep 2007	A1
20070208210	Gelfand et al.	Sep 2007	A1
20070208256	Marilla	Sep 2007	A1
20070208301	Evard et al.	Sep 2007	A1
20070219576	Cangialosi	Sep 2007	A1
20070225781	Saadat et al.	Sep 2007	A1
20070233170	Gertner	Oct 2007	A1
20070239062	Chopra et al.	Oct 2007	A1
20070248639	Demopulos et al.	Oct 2007	A1
20070249703	Mewshaw et al.	Oct 2007	A1
20070254833	Hunter et al.	Nov 2007	A1
20070265687	Deem et al.	Nov 2007	A1
20070278103	Hoerr et al.	Dec 2007	A1
20070282302	Wachsman et al.	Dec 2007	A1
20070292411	Salcedo et al.	Dec 2007	A1
20070293782	Marino	Dec 2007	A1
20070299043	Hunter et al.	Dec 2007	A1
20080004673	Rossing et al.	Jan 2008	A1
20080009927	Vilims	Jan 2008	A1
20080015501	Gertner	Jan 2008	A1
20080021408	Jacobsen et al.	Jan 2008	A1
20080033049	Mewshaw	Feb 2008	A1
20080039746	Hissong et al.	Feb 2008	A1
20080039830	Munger et al.	Feb 2008	A1
20080051454	Wang	Feb 2008	A1
20080064957	Spence	Mar 2008	A1
20080071269	Hilario et al.	Mar 2008	A1
20080071306	Gertner	Mar 2008	A1
20080082109	Moll et al.	Apr 2008	A1
20080086072	Bonutti et al.	Apr 2008	A1
20080091193	Kauphusman et al.	Apr 2008	A1
20080097251	Babaev	Apr 2008	A1
20080097426	Root et al.	Apr 2008	A1
20080108867	Zhou	May 2008	A1
20080119879	Brenneman et al.	May 2008	A1
20080125772	Stone et al.	May 2008	A1
20080132450	Lee et al.	Jun 2008	A1
20080140002	Ramzipoor et al.	Jun 2008	A1
20080147002	Gertner	Jun 2008	A1
20080161662	Golijanin et al.	Jul 2008	A1
20080161717	Gertner	Jul 2008	A1
20080161801	Steinke et al.	Jul 2008	A1
20080171974	Lafontaine et al.	Jul 2008	A1
20080172035	Starksen et al.	Jul 2008	A1
20080172104	Kieval et al.	Jul 2008	A1
20080188912	Stone et al.	Aug 2008	A1
20080188913	Stone et al.	Aug 2008	A1
20080208162	Joshi	Aug 2008	A1
20080208169	Boyle et al.	Aug 2008	A1
20080213331	Gelfand et al.	Sep 2008	A1
20080215117	Gross	Sep 2008	A1
20080221448	Khuri-Yakub et al.	Sep 2008	A1
20080234790	Bayer et al.	Sep 2008	A1
20080243091	Humphreys et al.	Oct 2008	A1
20080245371	Gruber	Oct 2008	A1
20080249525	Lee et al.	Oct 2008	A1
20080249547	Dunn	Oct 2008	A1
20080255550	Bell	Oct 2008	A1
20080255642	Zarins et al.	Oct 2008	A1
20080262489	Steinke	Oct 2008	A1
20080275484	Gertner	Nov 2008	A1
20080281312	Werneth et al.	Nov 2008	A1
20080281315	Gines	Nov 2008	A1
20080281347	Gertner	Nov 2008	A1
20080287918	Rosenman et al.	Nov 2008	A1
20080294037	Richter	Nov 2008	A1
20080300618	Gertner	Dec 2008	A1
20080312644	Fourkas et al.	Dec 2008	A1
20080312673	Viswanathan et al.	Dec 2008	A1
20080317818	Griffith et al.	Dec 2008	A1
20090012514	Moonen et al.	Jan 2009	A1
20090018486	Goren et al.	Jan 2009	A1
20090018609	DiLorenzo	Jan 2009	A1
20090024194	Arcot-Krishnamurthy et al.	Jan 2009	A1
20090030312	Hadjicostis	Jan 2009	A1
20090036948	Levin et al.	Feb 2009	A1
20090043372	Northrop et al.	Feb 2009	A1
20090054082	Kim et al.	Feb 2009	A1
20090062873	Wu et al.	Mar 2009	A1
20090069671	Anderson	Mar 2009	A1
20090074828	Alexis et al.	Mar 2009	A1
20090076409	Wu et al.	Mar 2009	A1
20090088735	Abboud et al.	Apr 2009	A1
20090105631	Kieval	Apr 2009	A1
20090112202	Young	Apr 2009	A1
20090118620	Tgavalekos et al.	May 2009	A1
20090118726	Auth et al.	May 2009	A1
20090125099	Weber et al.	May 2009	A1
20090131798	Minar et al.	May 2009	A1
20090143640	Saadat et al.	Jun 2009	A1
20090156988	Ferren et al.	Jun 2009	A1
20090157057	Ferren et al.	Jun 2009	A1
20090157161	Desai et al.	Jun 2009	A1
20090171333	Hon	Jul 2009	A1
20090192558	Whitehurst et al.	Jul 2009	A1
20090198223	Thilwind et al.	Aug 2009	A1
20090203962	Miller et al.	Aug 2009	A1
20090203993	Mangat et al.	Aug 2009	A1
20090204170	Hastings et al.	Aug 2009	A1
20090210953	Moyer et al.	Aug 2009	A1
20090216317	Cromack et al.	Aug 2009	A1
20090221955	Babaev	Sep 2009	A1
20090226429	Salcedo et al.	Sep 2009	A1
20090240249	Chan et al.	Sep 2009	A1
20090247933	Maor et al.	Oct 2009	A1
20090247966	Gunn et al.	Oct 2009	A1
20090248012	Maor et al.	Oct 2009	A1
20090253974	Rahme	Oct 2009	A1
20090264755	Chen et al.	Oct 2009	A1
20090270850	Zhou et al.	Oct 2009	A1
20090281533	Ingle et al.	Nov 2009	A1
20090287137	Crowley	Nov 2009	A1
20090318749	Stolen et al.	Dec 2009	A1
20100009267	Chase et al.	Jan 2010	A1
20100030061	Canfield et al.	Feb 2010	A1
20100048983	Ball et al.	Feb 2010	A1
20100049099	Thapliyal et al.	Feb 2010	A1
20100049186	Ingle et al.	Feb 2010	A1
20100049188	Nelson et al.	Feb 2010	A1
20100049191	Habib et al.	Feb 2010	A1
20100049283	Johnson	Feb 2010	A1
20100069837	Rassat et al.	Mar 2010	A1
20100076299	Gustus et al.	Mar 2010	A1
20100076425	Carroux	Mar 2010	A1
20100087782	Ghaffari et al.	Apr 2010	A1
20100106005	Karczmar et al.	Apr 2010	A1
20100114244	Manda et al.	May 2010	A1
20100125239	Perry et al.	May 2010	A1
20100125268	Gustus et al.	May 2010	A1
20100130836	Malchano et al.	May 2010	A1
20100137860	Demarais et al.	Jun 2010	A1
20100137952	Demarais et al.	Jun 2010	A1
20100160903	Krespi	Jun 2010	A1
20100160906	Jarrard	Jun 2010	A1
20100168624	Sliwa	Jul 2010	A1
20100168731	Wu et al.	Jul 2010	A1
20100168739	Wu et al.	Jul 2010	A1
20100174282	Demarais et al.	Jul 2010	A1
20100191112	Demarais et al.	Jul 2010	A1
20100191232	Boveda	Jul 2010	A1
20100204560	Salahieh et al.	Aug 2010	A1
20100217162	Hissong et al.	Aug 2010	A1
20100222786	Kassab	Sep 2010	A1
20100222851	Deem et al.	Sep 2010	A1
20100222854	Demarais et al.	Sep 2010	A1
20100228122	Keenan et al.	Sep 2010	A1
20100249604	Hastings et al.	Sep 2010	A1
20100249702	Magana et al.	Sep 2010	A1
20100249773	Clark et al.	Sep 2010	A1
20100256616	Katoh et al.	Oct 2010	A1
20100268217	Habib	Oct 2010	A1
20100268307	Demarais et al.	Oct 2010	A1
20100284927	Lu et al.	Nov 2010	A1
20100286684	Hata et al.	Nov 2010	A1
20100298821	Garbagnati	Nov 2010	A1
20100305036	Barnes et al.	Dec 2010	A1
20100312141	Keast et al.	Dec 2010	A1
20100324472	Wulfman	Dec 2010	A1
20110009750	Taylor et al.	Jan 2011	A1
20110021976	Li et al.	Jan 2011	A1
20110034832	Cioanta et al.	Feb 2011	A1
20110040324	McCarthy et al.	Feb 2011	A1
20110044942	Puri et al.	Feb 2011	A1
20110060324	Wu et al.	Mar 2011	A1
20110071400	Hastings et al.	Mar 2011	A1
20110071401	Hastings et al.	Mar 2011	A1
20110077498	McDaniel	Mar 2011	A1
20110092781	Gertner	Apr 2011	A1
20110092880	Gertner	Apr 2011	A1
20110104061	Seward	May 2011	A1
20110112400	Emery et al.	May 2011	A1
20110118598	Gertner	May 2011	A1
20110118600	Gertner	May 2011	A1
20110118726	De La Rama et al.	May 2011	A1
20110130708	Perry et al.	Jun 2011	A1
20110137155	Weber et al.	Jun 2011	A1
20110144479	Hastings et al.	Jun 2011	A1
20110146673	Keast et al.	Jun 2011	A1
20110166499	Demarais et al.	Jul 2011	A1
20110178403	Weng et al.	Jul 2011	A1
20110178570	Demarais	Jul 2011	A1
20110200171	Beetel et al.	Aug 2011	A1
20110202098	Demarais et al.	Aug 2011	A1
20110207758	Sobotka et al.	Aug 2011	A1
20110208096	Demarais et al.	Aug 2011	A1
20110257523	Hastings et al.	Oct 2011	A1
20110257564	Demarais et al.	Oct 2011	A1
20110257622	Salahieh et al.	Oct 2011	A1
20110257641	Hastings et al.	Oct 2011	A1
20110257642	Griggs, III	Oct 2011	A1
20110263921	Vrba et al.	Oct 2011	A1
20110264011	Wu et al.	Oct 2011	A1
20110264075	Leung et al.	Oct 2011	A1
20110264086	Ingle	Oct 2011	A1
20110264116	Kocur et al.	Oct 2011	A1
20110270238	Rizq et al.	Nov 2011	A1
20110306851	Wang	Dec 2011	A1
20110307034	Hastings et al.	Dec 2011	A1
20110319809	Smith	Dec 2011	A1
20120029496	Smith	Feb 2012	A1
20120029500	Jenson	Feb 2012	A1
20120029505	Jenson	Feb 2012	A1
20120029509	Smith	Feb 2012	A1
20120029510	Haverkost	Feb 2012	A1
20120029511	Smith et al.	Feb 2012	A1
20120029512	Willard et al.	Feb 2012	A1
20120029513	Smith et al.	Feb 2012	A1
20120059241	Hastings et al.	Mar 2012	A1
20120059286	Hastings et al.	Mar 2012	A1
20120065506	Smith	Mar 2012	A1
20120065554	Pikus	Mar 2012	A1
20120095461	Herscher et al.	Apr 2012	A1
20120101413	Beetel et al.	Apr 2012	A1
20120101490	Smith	Apr 2012	A1
20120101538	Ballakur et al.	Apr 2012	A1
20120109021	Hastings et al.	May 2012	A1
20120116382	Ku et al.	May 2012	A1
20120116383	Mauch et al.	May 2012	A1
20120116392	Willard	May 2012	A1
20120116438	Salahieh et al.	May 2012	A1
20120116486	Naga et al.	May 2012	A1
20120123243	Hastings	May 2012	A1
20120123258	Willard	May 2012	A1
20120123261	Jenson et al.	May 2012	A1
20120123303	Sogard et al.	May 2012	A1
20120123406	Edmunds et al.	May 2012	A1
20120130289	Demarais et al.	May 2012	A1
20120130345	Levin et al.	May 2012	A1
20120130359	Turovskiy	May 2012	A1
20120130360	Buckley et al.	May 2012	A1
20120130362	Hastings et al.	May 2012	A1
20120130368	Jenson	May 2012	A1
20120130458	Ryba et al.	May 2012	A1
20120136344	Buckley et al.	May 2012	A1
20120136349	Hastings	May 2012	A1
20120136350	Goshgarian et al.	May 2012	A1
20120136417	Buckley et al.	May 2012	A1
20120136418	Buckley et al.	May 2012	A1
20120143181	Demarais et al.	Jun 2012	A1
20120143293	Mauch et al.	Jun 2012	A1
20120143294	Clark et al.	Jun 2012	A1
20120150267	Buckley et al.	Jun 2012	A1
20120157986	Stone et al.	Jun 2012	A1
20120157987	Steinke et al.	Jun 2012	A1
20120157988	Stone et al.	Jun 2012	A1
20120157989	Stone et al.	Jun 2012	A1
20120157992	Smith et al.	Jun 2012	A1
20120157993	Jenson et al.	Jun 2012	A1
20120158101	Stone et al.	Jun 2012	A1
20120158104	Huynh et al.	Jun 2012	A1
20120172837	Demarais et al.	Jul 2012	A1
20120172870	Jenson et al.	Jul 2012	A1
20120184952	Jenson et al.	Jul 2012	A1
20120197198	Demarais et al.	Aug 2012	A1
20120197252	Deem et al.	Aug 2012	A1
20120232409	Stahmann et al.	Sep 2012	A1
20120265066	Crow et al.	Oct 2012	A1
20120265198	Crow et al.	Oct 2012	A1
20130012844	Demarais et al.	Jan 2013	A1
20130012866	Deem et al.	Jan 2013	A1
20130012867	Demarais et al.	Jan 2013	A1
20130013024	Levin et al.	Jan 2013	A1
20130023865	Steinke et al.	Jan 2013	A1
20130035681	Subramaniam et al.	Feb 2013	A1
20130066316	Steinke et al.	Mar 2013	A1
20130085489	Fain et al.	Apr 2013	A1
20130090563	Weber	Apr 2013	A1
20130090578	Smith et al.	Apr 2013	A1
20130090647	Smith	Apr 2013	A1
20130090649	Smith et al.	Apr 2013	A1
20130090650	Jenson et al.	Apr 2013	A1
20130090651	Smith	Apr 2013	A1
20130090652	Jenson	Apr 2013	A1
20130096550	Hill	Apr 2013	A1
20130096553	Hill et al.	Apr 2013	A1
20130096554	Groff et al.	Apr 2013	A1
20130096604	Hanson et al.	Apr 2013	A1
20130110106	Richardson	May 2013	A1
20130116687	Willard	May 2013	A1
20130165764	Scheuermann et al.	Jun 2013	A1
20130165844	Shuros et al.	Jun 2013	A1
20130165916	Mathur et al.	Jun 2013	A1
20130165917	Mathur et al.	Jun 2013	A1
20130165920	Weber et al.	Jun 2013	A1
20130165923	Mathur et al.	Jun 2013	A1
20130165924	Mathur et al.	Jun 2013	A1
20130165925	Mathur et al.	Jun 2013	A1
20130165926	Mathur et al.	Jun 2013	A1
20130165990	Mathur et al.	Jun 2013	A1
20130172815	Perry et al.	Jul 2013	A1
20130172872	Subramaniam et al.	Jul 2013	A1
20130172877	Subramaniam et al.	Jul 2013	A1
20130172878	Smith	Jul 2013	A1
20130172879	Sutermeister	Jul 2013	A1
20130172880	Willard	Jul 2013	A1
20130172881	Hill et al.	Jul 2013	A1

Foreign Referenced Citations (168)

Number	Date	Country
2384866	May 2001	CA
101583323	Nov 2009	CN
102271607	Dec 2011	CN
10038737	Feb 2002	DE
102005041601	Apr 2007	DE
102008048616	Apr 2010	DE
558297	Sep 1993	EP
647435	Apr 1995	EP
634910	Aug 1997	EP
868884	Oct 1998	EP
1005838	Jun 2000	EP
1053720	Nov 2000	EP
1055399	Nov 2000	EP
1064886	Jan 2001	EP
1180004	Feb 2002	EP
1181895	Feb 2002	EP
1297795	Jun 2002	EP
1264613	Dec 2002	EP
1286625	Mar 2003	EP
1332724	Aug 2003	EP
1335677	Aug 2003	EP
866675	Oct 2003	EP
1433448	Jun 2004	EP
1442719	Aug 2004	EP
1547537	Jun 2005	EP
1634542	Mar 2006	EP
1698296	Jun 2006	EP
1709922	Oct 2006	EP
1874211	Jan 2008	EP
1906853	Apr 2008	EP
1946712	Jul 2008	EP
1961394	Aug 2008	EP
1715798	Apr 2009	EP
1620156	Jul 2009	EP
2076193	Jul 2009	EP
2091455	Aug 2009	EP
2092957	Aug 2009	EP
2197533	Jun 2010	EP
2208506	Jul 2010	EP
1579889	Aug 2010	EP
2241279	Oct 2010	EP
2092957	Jan 2011	EP
2329859	Jun 2011	EP
2349044	Aug 2011	EP
2027882	Oct 2011	EP
2378956	Oct 2011	EP
2037840	Dec 2011	EP
2204134	Apr 2012	EP
2320821	Oct 2012	EP
2313062	Nov 1997	GB
2453601	Apr 2009	GB
2456301	Jul 2009	GB
0779991	Mar 1995	JP
1995-213621	Aug 1995	JP
1995-313603	Dec 1995	JP
2001008944	Jan 2001	JP
2003-510126	Mar 2003	JP
WO 9103207	Mar 1991	WO
WO 9117731	Nov 1991	WO
WO 9222239	Dec 1992	WO
WO 9320747	Oct 1993	WO
WO 9320770	Oct 1993	WO
WO 9418896	Sep 1994	WO
WO 9428809	Dec 1994	WO
WO 9501751	Jan 1995	WO
WO 9531142	Nov 1995	WO
WO 9634559	Nov 1996	WO
9639086	Dec 1996	WO
WO 9703604	Feb 1997	WO
WO 9717104	May 1997	WO
WO 9720510	Jun 1997	WO
WO 9732532	Sep 1997	WO
WO 9740760	Nov 1997	WO
WO 9745156	Dec 1997	WO
WO 9818393	May 1998	WO
WO 9829030	Jul 1998	WO
WO 9834565	Aug 1998	WO
WO 9835638	Aug 1998	WO
WO 9840023	Sep 1998	WO
9858588	Dec 1998	WO
9900060	Jan 1999	WO
WO 9900060	Jan 1999	WO
WO 9916370	Apr 1999	WO
WO 9921608	May 1999	WO
WO 9934741	Jul 1999	WO
WO 9944522	Sep 1999	WO
WO 0001313	Jan 2000	WO
WO 0010475	Mar 2000	WO
0047118	Aug 2000	WO
WO 0051513	Sep 2000	WO
WO 0059394	Oct 2000	WO
WO 0062727	Oct 2000	WO
WO 0064387	Nov 2000	WO
WO 0069376	Nov 2000	WO
WO 0072909	Dec 2000	WO
WO 0122897	Apr 2001	WO
WO 0137746	May 2001	WO
WO 0187172	May 2001	WO
WO 0174255	Oct 2001	WO
WO 0187154	Nov 2001	WO
WO 0195820	Dec 2001	WO
WO 0215807	Feb 2002	WO
WO 0228475	Apr 2002	WO
WO 0239915	May 2002	WO
WO 02058549	Aug 2002	WO
WO 02080766	Oct 2002	WO
WO 02087679	Nov 2002	WO
WO 02089686	Nov 2002	WO
03026525	Apr 2003	WO
WO 03077781	Sep 2003	WO
WO 2004047659	Jun 2004	WO
WO 2004049976	Jun 2004	WO
WO 2004064606	Aug 2004	WO
WO 2004069300	Aug 2004	WO
WO 2004076146	Sep 2004	WO
2004100813	Nov 2004	WO
WO 2004098694	Nov 2004	WO
2004110258	Dec 2004	WO
WO 2004105807	Dec 2004	WO
WO 2005007000	Jan 2005	WO
WO 2005037070	Apr 2005	WO
WO 2005041748	May 2005	WO
WO 2005074829	Aug 2005	WO
WO 2006041881	Apr 2006	WO
2006105121	Oct 2006	WO
WO 2006105121	Oct 2006	WO
WO 2006116198	Nov 2006	WO
WO 2007011634	Jan 2007	WO
WO 2007014063	Feb 2007	WO
WO 2007047870	Apr 2007	WO
WO 2007113865	Oct 2007	WO
WO 2007135431	Nov 2007	WO
WO 2007146215	Dec 2007	WO
2008014465	Jan 2008	WO
WO 2008003058	Jan 2008	WO
WO 2008009972	Jan 2008	WO
WO 2008010150	Jan 2008	WO
WO 2008036281	Mar 2008	WO
WO 2008049084	Apr 2008	WO
WO 2008061152	May 2008	WO
WO 2008102363	Aug 2008	WO
WO 2009036471	Mar 2009	WO
WO 2009082635	Jul 2009	WO
WO 2009088678	Jul 2009	WO
WO 2009113064	Sep 2009	WO
2009121017	Oct 2009	WO
WO 2009121017	Oct 2009	WO
WO 2009137819	Nov 2009	WO
WO 2010042653	Apr 2010	WO
WO 2010048007	Apr 2010	WO
WO 2010056771	May 2010	WO
WO 2010057043	May 2010	WO
2010067360	Jun 2010	WO
WO 2010070766	Jun 2010	WO
2010102310	Sep 2010	WO
WO 2010099207	Sep 2010	WO
WO 2010120944	Oct 2010	WO
WO 2010134503	Nov 2010	WO
2011005901	Jan 2011	WO
2011053757	May 2011	WO
2011053772	May 2011	WO
WO 2011055143	May 2011	WO
WO 2011060339	May 2011	WO
2011091069	Jul 2011	WO
2011130534	Oct 2011	WO
WO 2011126580	Oct 2011	WO
2012019156	Feb 2012	WO
2013049601	Apr 2013	WO

Non-Patent Literature Citations (152)

Entry
US 8,398,630, 03/2013, Demarais et al. (withdrawn)
CardioVascular Technologies Inc., “Heated Balloon Device Technology,” 11 pages, 2008.
Strategic Business Development, Inc., “Thermal and Disruptive Angioplasty: A Physician's Guide,” 8 pages, 1990.
Zhang et al., “Non-contact Radio-Frequency Ablation for Obtaining Deeper Lesions,” IEEE Transaction on Biomedical Engineering, vol. 50, No. 2, 6 pages, Feb. 2003.
Lazebnik et al., “Tissue Strain Analytics Virtual Touch Tissue Imaging and Qualification,” Siemens Whitepaper, Oct. 2008, 7 pages.
Han et al., “Third-Generation Cryosurgery for Primary and Recurrent Prostate Caner,” BJU International, vol. 93, pp. 14-18.
Zhou et al., “Mechanism Research of Ciyoanalgesia,” Forefront Publishing Group, 1995.
Florete, “Cryoblative Procedure for Back Pain,” Jacksonville Medicine, Oct. 1998, 10 pages.
Stevenson, “Irrigated RF Ablation: Power Titration and Fluid Management for Optimal Safety Efficacy,” 2005, 4 pages.
Giliatt et al., “The Cause of Nerve Damage in Acute Compression,” Trans Am Neurol Assoc, 1974: 99; 71-4.
Omura et al., “A Mild Acute Compression Induces Neurapraxia in Rat Sciatic Nerve,” The International Journal of Neuroscience, vol. 114 (12), pp. 1561-1572.
Baun, “Interaction with Soft Tissue,” Principles of General & Vascular Sonography, Chapter 2, pp. 23-24, Before Mar. 2012.
Blue Cross Blue Shield Medicaly Policy, “Surgery Section—MRI-Guided Focused Ultrasound (MRgFUS) for the Treatment of Uterine Fibroids and Other Tumors,” 2005, 5 pages.
Gentry et al., “Combines 3D Intracardiac Echo and Ultrasound Ablation,” Medical Imaging 2003: Ultrasonic and Signal Processing, vol. 5035, 2003, pp. 166-173.
Lafon et al., “Optmizing the Shape of Ultrasound Transducers for Interstitial Thermal Ablations,” MEd Phys. Mar. 2002; 29(3): 290-7 (abstract only).
G. Ter Haar, “Ultrasound Focal Beam Surgery,” Ultrasound in Med. & Biol., 1995, vol. 21, No. 9, pp. 1089-1100.
Seip et al., “Transurethral High Intensity Focused Ultrasound: Catheter Based Prototypes and Experimental Results,” IEEE Ultrasonics Symposium Proceeding, 2000, 4 pages.
Toytman et al., “Tissue Dissection with Ultrafast Laser Using Extended and Multiple Foci,” SPIE Proceeding, Optical Interactions with Tissues and Cells XXI, vol. 7562, 2010, 10 pages.
Zhoue et al., “Non-Thermal Ablation of Rabbit Liver VX2 Tumore by Pulsed High Intensity Focused Ultrasound Contrast Agent: Pathological Characteristics,” World Journal of Gastroenterology, vol. 14(43), Nov. 21, 2008, pp. 6743-6747.
Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg” Phys Med Biol 1993, 38 1-12 (abstract).
Cardiovascular Technologies, Inc., “Heated Balloon Device Technology” [Presentation], 2007-2008, 11 pages total. Retrieved from: <<http://www.cvtechinc.com/pr/presoCVT—Heated—Balloon—Tech.pdf>>.
Carrington, “Future of CVI: It's All About the Plaque.” Diagnostic Imaging Special Edition Forum [online] [retrieved on Sep. 3, 2003] Retreived from the Internet:,http://dimag.com/specialedition/cardiacimg.shtml> 5 pages total.
Cimino, “Preventing Plaque Attack”, [online] [retrieved on Sep. 3, 2003] Retrieved from the Internet: <http://Masshightech.com/displayarticledetail.ap?art—id=52283&cat—id=10>, 3 pages total.
Dahm et al, “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate”, Am J Cardiol, 2002; 90(1): 68-70.
De Korte C L. et al., “Characterization of Placque Components with Intravascular Ultrasound Elastography in Human Femoral and Coronary Arterties In Vitro,” Circulation 2000;102:617-623.
Durney C., et al., Radiofrequency Radiation Dosimetry Handbook (with table of contents), Oct. 1986, 4th ed., 7 pages, Armstrong Laboratory (AFMC) Occupational and Environmental Health Directorate Radiofrequency Radiation Division, USAF School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooks Air Force Base, http://www.brooks.af.mil/AFRL/HED/hedr/reports/handbook/home.htm.
Fournier-Desseux et al. “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography”, Physiol. Meas. (2005) 26:337-349.
Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction”, Abstract #2925, AHA (2002), 1 page total.
Fujita, “Sarpogrelate, An Antagonist of 5-HT2a Receptor Treatment Reduces Restenosis After Coronary Stenting”, Abstract #2927, AHA (2002), 1 page total.
Gabriel C, et al., Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies (with table of contents), Jun. 1996, 17 pages, Armstrong Laboratory (AFMC) Occupational and Environmental Health Directorate Radiofrequency Radiation Division, USAF School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooks Air Force Base, http://www.brooks.af.mil/AFRL/HED/hedr/reports/dielectric/Report/Report.html.
Gabriel C, et al., Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies, Appendi04-10-2009 A, Jun. 1996, 21 pages, Armstrong Laboratory (AFMC) Occupational and Environmental Health Directorate Radiofrequency Radiation Division, USAF School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooks Air Force Base, http://www.brooks.af.mil/AFRL/HED/hedr/reports/dielectric/Appendi04-10-2009.A/Appendi04-10-2009.A.html.
Gabriel C, et al., Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies, Appendi04-10-2009 C, Jun. 1996, 6 pages, Armstrong Laboratory (AFMC) Occupational and Environmental Health Directorate Radiofrequency Radiation Division, USAF School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooks Air Force Base, http://www.brooks.af.mil/AFRL/HED/hedr/reports/dielectric/Appendi04-10-2009.C/Appendi04-10-2009.C.html.
Gregory et al., “Liquid Core Light Guide for Laser Angioplasty”, Journal of Quantum Electronics, vol. 26, No. 12, (Dec. 1990), pp. 2289-2296.
Intraluminal, Product description [online] [retrieved on Sep. 3, 2003] Retrieved from the Internet: http://www.intraluminal.com/products/inde04-10-2009 .html> 1 page total.
Kaplan et al., “Healing after arterial dilatation with radiofrequency thermal and nonthermal balloon angioplasty systems,” J Invest Surg. Jan.-Feb. 1993;6(1):33-52.
Kolata, “New Studies Question Value of Opening Arteries”, New York Times [online] [retrieved on Jan. 25, 2005]. Retrieved from the Internet: <http://nytimes.com/2004/03/21/health/21HEAR.html?ei=5070&en=641bc03214e&e04-10-2009 =11067>, 5 pages total.
Konings M K, et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, vol. 51, No. 4, Apr. 2004.
Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes”, J Refract Surg, vol. 14, (Sep./Oct. 1998), pp. 541-548.
LightLab Imaging Technology, “Advantages of OCT”, [online] [retrieved on Sep. 3, 2003]. Retrieved from the Internet: <http:www.lightlabimaging.com/advantage.html> 2 pages total.
LightLab Imaging Technology, “Image Gallery”, [online] [retrieved on Sep. 3, 2003]. Retrieved from the Internet: <http:lightlabimaging.com/gallery/cvpstill.html> 4 pages total.
LightLab Imaging Technology, “LightLab Imaging Starts US Cardiology Clinical Investigations”, LightLab Company Press Release, [online] [retrieved on Sep. 3, 2003]. Retrieved from the Internet: <http://www.lighlabimaging.com/press/cardtrails.html> 2 pages total.
LightLab Imaging Technology, “LightLab Sees Bright Prospects for Cardiac Application of OCT Technology” The Graysheet Medical Devices Diagnostics & Instrumentation, vol. 27, No. 35, (Aug. 27, 2001) [online] [retrieved on Sep. 3, 2003]. Retrieved from the Internet: <http://www.lighlabimaging.com/press/graysheet.html> 1 page total.
LightLab Imaging Technology, “What is OCT?”, [online] [retrieved on Sep. 3, 2003]. Retrieved from the Internet: <http:lightlabimaging.com/oct.html.> 2 pages total.
LightLab Imaging Technology, “Why use OCT?”, [online] [retrieved on Sep. 3, 2003]. Retrieved from the Internet: <http:lightlabimaging.com/whyoct.html> 2 pages total.
Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results”, Abstract #2929, AHA (2002), 1 page total.
Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients”, Abstract #2928, AHA (2002), 1 page total.
MIT TechTalk, “Laser Catheter to Aid Coronary Surgery”, Jan. 9, 1991 [online] [retrieved on Feb. 7, 2005]. Retrieved from the Internet : <http://web.mit.edu/newsoffice/tt/1991/jan09/24037.html> 4 pages total.
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization”, N. Engl J Med, vol. 346, No. 23, (Jun. 6, 2002), pp. 1773-1779.
Müller et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation”, CardioVas. Intervent. Radiol., (1993) 16: 303-307.
Nair A, et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 51 No. 4, Apr. 2004.
Popma et al., “Chapter 38—Percutaneous Coronary and Valvular Intervention”, Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed., (2001) W.B> Saunders Company, pp. 1364-1405.
Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition with Raman Spectroscopy,” Circulation 97:878-885 (1998).
Scheller et al., “Potential Solutions to the Current Problem: Coated Balloon,” EuroIntervention, Aug. 4, 2008; Suppl C: C63-66.
Scheller, “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries”, Abstract #2227, AHA (2002), 2 pages total.
Shaffer, “Scientific Basis of Laser Energy”, Clin Sports Med 2002; 21(4):585-598.
Shmatukha A V, et al., “MRI temperature mapping during thermal balloon angioplasty,” Phys Med Biol 51, (2006) N163-N171.
Slager et al., “Vaporization of Atherosclerotic Placques by Spark Erosion,” J Am Coll Cardiol, vol. 5 (Jun. 1985) pp. 1382-1386.
Stiles et al., “Simulated Charactization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEEE Transactions on Biomedical Engineering, (Jul. 2003), 5(4):916-921.
Süselbeck et al. “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance system”, Basic Res Cardiol (2005) 100:446-452.
Suselbeck T, et al., “In vivo intravascular electrical impedance spectroscopy using a new catheter with integrated microelectrodes,” Basic Res Cardiol 100:28-34 (2005).
Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis During Angioplasty of the Leg,” N Engl J Med, Feb. 14, 2008; 358(7): 689-699; retrieved from the Internet: <<http://content.nejm.org/cgi/reprint/358/7/689.pdf>>.
Van Den Berg, “Light Echoes Image the Human Body”, OLE, Oct. 2001, pp. 35-37.
Volcano Therapeutics, “Product—Functional Measurement”, [online] [retrieved on Sep. 3, 2003]. Retrieved from the Internet: <http://www.volcanotherapeutics.com/pages/products/functional—measurement-us.html> 2 pages total.
Examiner's Report of Canadian Patent Application No. 2,539,026, mailed Feb. 6, 2012, 4 pages total.
Office Action issued in Chinese Patent Application No. 200480030163.9, mailed Jan. 16, 2009, 8 pages total.
Office Action issued in Chinese Patent Application No. 200480030163.9, mailed Mar. 28, 2008, 7 pages total.
Office Action issued in Chinese Patent Application No. 200480030163.9, mailed Aug. 31, 2007, 8 pages total.
Office Action issued in Chinese Patent Application No. 200480030163.9, mailed Jul. 31, 2009, 5 pages total.
Supplementary Partial European Search Report of Application No. 04816863.7, mailed May 8, 2009, 7 pages total.
Office Action issued in European Application No. 04816863.7, mailed Jun. 4, 2010, 5 pages total.
Office Action issued in European Application No. 04816863.7, mailed Dec. 5, 2011, 4 pages total.
Office Action issued in European Application No. 04816863.7, mailed Jan. 22, 2010, 6 pages total.
Formal Inquiry issued in Japanese Patent Application No. 2006-526351, mailed Jan. 17, 2012, 5 pages total.
Notice of the Reason for Refusal issued in Japanese Patent Application No. 2006-526351, mailed Apr. 27, 2010, 6 pages total.
Final Decision of Rejection issued in Japanese Patent Application No. 2006-526351, mailed Jan. 18, 2011, 4 pages total.
European Search Report and Search Opinion of EP Patent Application No. 12151957.3, mailed Apr. 16, 2012, 8 pages total.
Office Action issued in Chinese Patent Application No. 200680016424.0, mailed Apr. 13, 2010, 10 pages total.
European Search Report and Search Opinion of EP Patent Application No. 06748830.4, mailed Nov. 16, 2009, 12 pages total.
Partial European Search Report of EP Patent Application No. 11191822.3, mailed Mar. 19, 2012, 7 pages total.
Office Action issued in Chinese Patent Application No. 20111031923.X, mailed Nov. 17, 2011, 16 pages total.
Office Action issued in Chinese Patent Application No. 20111031923.X, mailed May 22, 2012, 10 pages total.
Examiner's First Report of Australian Patent Application No. 2007310988, mailed May 23, 2012, 4 pages total.
European Search Report and Search Opinion of EP Patent Application No. 07844421.3, mailed Jan. 4, 2010, 15 pages total.
European Search Report and Search Opinion of EP Patent Application No. 12155447.1, mailed May 10, 2012, 6 pages total.
International Search Report and Written Opinion of PCT Application No. PCT/US2009/064027, mailed Jan. 19, 2010, 9 pages total.
European Search Report and Search Opinion of EP Patent Application No. 07844417.1, mailed Nov. 5, 2009.
European Search Report and Search Opinion of EP Patent Application No. 12154120.5, mailed May 8, 2012, 8 pages total.
European Search Report and Search Opinion of EP Patent Application No. 07844424.7, mailed Nov. 11, 2009, 11 pages total.
Partial European Search Report of EP Patent Application No. 12154069.4, mailed May 10, 2012, 5 pages total.
International Search Report and Written Opinion of PCT Application No. PCT/US2009/064465, mailed Jan. 13, 2010, 13 pages total.
International Search Report of PCT Application No. PCT/US09/57728, mailed Nov. 30, 2009, 10 pages total.
International Search Report and Written Opinion of PCT/US2010/034789, mailed Jul. 9, 2010, 13 pages total.
International Search Report and Written Opinion of PCT/US2011/00661, mailed Nov. 18, 2011, 14 pages total.
Brown et al., “Observations on the shrink temperature of collagen and its variations with age and disease,” Ann Rheum Dis, Jun. 1, 1958, 17(2):196-208.
Notice of the Reason for Refusal issued in Japanese Patent Application No. 2009-533544, mailed Jun. 19, 2012, 3 pages total.
Summons to Attend Oral Proceedings of EP Patent Application No. 07844424.7, mailed Jul. 5, 2012, 7 pages total.
European Search Report and Search Opinion of EP Patent Application No. 11191822.3, mailed Jun. 13, 2012, 13 pages total.
Office Action issued in European Application No. 07844421.3, mailed Aug. 23, 2012, 5 pages total.
Notice of the Reason for Refusal issued in Japanese Patent Application No. 2009-533546, mailed Jun. 19, 2012, 6 pages total.
Extended European Search Report and Search Opinion of EP Patent Application No. 12154069.4, mailed Sep. 17, 2012, 13 pages total.
Notice of the Reason for Refusal issued in Japanese Patent Application No. 2006-526351, mailed Sep. 18, 2012, 20 pages total.
Office Action issued in Chinese Patent Application No. 201110031923.X, mailed on Sep. 6, 2012, 11 pages total.
Office Action issued in Australian Patent Application No. 2010248955, mailed Sep. 13, 2012, 4 pages total.
Van Den Berg, “Light echoes image the human body,” OLE, Oct. 2001, p. 35-37.
“IntraLuminal: Products,” IntraLuminal Therapeutics, Inc., 2003, p. 1-9.
“Laser Catheter to Aid Coronary Surgery,” TechTalk: MIT, Jan. 9, 1991, p. 1-4.
“Optical Coherence Tomography: LightLab Imaging Starts US Cardiology Clinical Investigations,” LightLab Imaging Technology, 2002.
“Optical Coherence Tomography: LightLab Sees Bright Prospects for Cardiac Application of OCT Technology,” LightLab Imaging Technology, 2001, vol. 27, No. 35.
“Products—Functional Measurement,” VOLCANO Functional Measurement Products US, Mar. 24, 2003, p. 1-2.
Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg,” Physics in Medicine and Biology, 1993, p. 1-12, vol. 38.
Carrington, “Future of CVI: It's all about plaque: Identification of vulnerable lesions, not ‘rusty pipes,’ could become cornerstone of preventive cardiology,” Diagnostic Imaging, 2001, p. 1-8.
Chen et al., “Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo,” EuroIntervention, 2013, p. 1-8.
Cimino, “Preventing plaque attack,” Mass High Tech, 2001, p. 1-2.
Dahm et al., “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate,” The American Journal of Cardiology, 2002, p. 68-70, vol. 90.
De Korte et al., “Characterization of Plaque Components With Intravascular Ultrasound Elastography in Human Femoral and Coronary Arteries In Vitro,” Circulation, Aug. 8, 2000, p. 617-623.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook,” Oct. 1986, p. 1-2, Fourth Edition.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook: Contents,” Oct. 1986, p. 1-5, Fourth Edition.
Fournier-Desseux et al., “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography,” Physiological Measurement, 2005, p. 337-349. Vo. 26, Institute of Physics Publishing.
Fram et al., “Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts Via the Coronary Sinus: In Vivo Canine Studies,” PACE, Aug. 1995, p. 1518-1530, vol. 18.
Fram et al., “Low Pressure Radiofrequency Balloon Angioplasty: Evaluation in Porcine Peripheral Arteries,” JACC, 1993, p. 1512-1521, vol. 21, No. 6, American College of Cardiology.
Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction,” American Heart Association, 2002.
Fujita et al., “Sarpogrelate, An Antagonist of 5-HT(2A) Receptor, Treatment Reduces Restenosis After Coronary Stenting,” American Heart Association, 2002.
Gabriel, “Appendix A: Experimental Data,” 1999, p. 1-21.
Gabriel, “Appendix C: Modeling the frequency dependence of the dielectric properties to a 4 dispersions spectrum,” p. 1-6, 1999 (see above).
Gregory et al., “Liquid Core Light Guide for Laser Angioplasty,” The Journal of Quantum Electronics, Dec. 1990, p. 2289-2296, vol. 26, No. 12.
Kaplan et al., “Healing after Arterial Dilatation with Radiofrequency Thermal and Nonthermal Balloon Angioplasty Sytems,” Journal of Investigative Surgery, 1993, p. 33-52, vol. 6.
Kolata, “New Studies Question Value of Opening Arteries,” The New York Times, Mar. 21, 2004, p. 1-5.
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, Aug. 1997, p. 439-446, vol. 16, No. 4.
Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes,” Journal of Refractive Surgery, Sep./Oct. 1998, p. 541-548.
Lee et al., “Thermal Compression and Molding of Atherosclerotic Vascular Tissue With Use of Radiofrequency Energy: Implications for Radiofrequency Balloon Angioplasty,” JACC, 1989, p. 1167-1175, vol. 13, No. 5, American College of Cardiology.
Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results,” American Heart Association, 2002, p. 2929.
Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients,” American Heart Association, 2002, p. 2928.
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization,” The New England Journal of Medicine, Jun. 6, 2012, p. 1773-1780, vol. 346, No. 23.
Muller-Leisse et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation,” CardioVascular and Interventional Radiology, 1993, p. 303-307, vol. 16.
Nair et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” IEEE Transactions on Ultrasonics, Apr. 2004, p. 420-431, vol. 51, No. 4.
Popma et al., “Percutaneous Coronary and Valvular Intervention,” p. 1364-1405.
Resar et al., “Endoluminal Sealing of Vascular Wall Disruptions With Radiofrequency-Heated Balloon Angioplasty,” Catheterization and Cardiovascular Diagnosis, 1993, p. 161-167, vol. 29.
Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition With Raman Spectroscopy,” Circulation, 1998, p. 878-885, vol. 97.
Schauerte et al., “Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation,” Circulation, 2000, p. 2774-2780, vol. 102.
Scheller et al., “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries,” American Heart Association, 2002, p. 2227.
Scheller et al., “Potential solutions to the current problem: coated balloon,” Eurolntervention, 2008, p. C63-C66, vol. 4 (Supplement C).
Shaffer, “Scientific basis of laser energy,” Clinics in Sports Medicine, 2002, p. 585-598, vol. 21.
Shmatukha et al., “MRI temperature mapping during thermal balloon angioplasty,” Physics in Medicine and Biology, 2006, p. N163-N171, vol. 51.
Slager et al., “Vaporization of Atherosclerotic Plaques by Spark Erosion,” J Am Coll Cardiol, 1985, p. 21-25.
Stiles et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEEE Transactions on Biomedical Engineering, Jul. 2003, p. 916-921, vol. 50, No. 7.
Suselbeck et al., “In vivo intravascular electric impedance spectroscopy using a new catheter with integrated microelectrodes,” Basic Res Cardiol, 2005, p. 28-34, vol. 100.
Suselbeck et al., “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance catheter system,” Basic Res Cardiol, 2005, p. 446-452, vol. 100.
Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg,” The New England Journal of Medicine, 2008, p. 689-699, vol. 358.
“Optical Coherence Tomography: Advantages of OCT,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Image Gallery Cardiovascular Procedures,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: What is OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Why Use OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.

Related Publications (1)

	Number	Date	Country
	20120095461 A1	Apr 2012	US

Provisional Applications (1)

	Number	Date	Country
	61342191	Apr 2010	US

Power generating and control apparatus for the treatment of tissue

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract